Fortress Biotech (FBIO) 10-Q 9 Aug 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 09, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Entity Registrant Name	Fortress Biotech, Inc.
Entity Central Index Key	1,429,260
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	FBIO
Entity Common Stock, Shares Outstanding		54,342,589

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 98,591	$ 113,915
Accounts receivable	5,321	7,758
Short-term investments (certificates of deposit)	35,000	36,002
Cash deposits with clearing organizations	836	1,041
Receivables from broker-dealers and clearing organizations	11,412	7,395
Forgivable loans receivable	1,598	1,616
Securities owned, at fair value	3,812	1,985
Inventory	299	171
Other receivables - related party	775	618
Prepaid expenses and other current assets	13,880	12,680
Total current assets	171,524	183,181
Property and equipment, net	14,163	9,513
Restricted cash	17,389	17,387
Long-term investments, at fair value	565	1,390
Intangible assets	13,614	15,223
Goodwill	18,645	18,645
Other assets	966	611
Total assets	236,866	245,950
Current liabilities
Accounts payable and accrued expenses	38,126	36,127
Accounts payable and accrued expenses - related party	73	222
Accrued commissions and payroll payable	10,652	10,065
Deferred clearing and marketing credits	681	786
Securities sold, not yet purchased, at fair value	8	151
Warrants issued - National	0	5,597
Interest payable	1,143	887
Interest payable - related party	94	97
Notes payable, short-term (net of debt discount of $0 and $973 at June 30, 2018 and December 31, 2017, respectively)	0	8,528
Subsidiary convertible note, short-term, at fair value	10,573	4,700
Deferred revenue	650	0
Derivative warrant liability	0	87
Other current liabilities	158	181
Total current liabilities	62,158	67,428
Notes payable, long-term (net of debt discount of $1,035 and $62 at June 30, 2018 and December 31, 2017, respectively)	73,456	43,222
Subsidiary convertible note, long-term, at fair value	0	10,059
Other long-term liabilities	4,987	4,739
Total liabilities	140,601	125,448
Stockholders' equity
Preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 1,000,000 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively; liquidation value of $25.00 per share	1	1
Common stock, $0.001 par value, 100,000,000 shares authorized, 53,987,074 and 50,991,285 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	54	51
Common stock issuable, 259,813 and 158,015 shares as of June 30, 2018 and December 31, 2017, respectively	776	500
Additional paid-in-capital	397,858	364,148
Accumulated deficit	(354,756)	(312,127)
Total stockholders' equity attributed to the Company	43,933	52,573
Non-controlling interests	52,332	67,929
Total stockholders' equity	96,265	120,502
Total liabilities and stockholders' equity	$ 236,866	$ 245,950

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument, Unamortized Discount, Current	$ 0	$ 973
Debt Instrument, Unamortized Discount, Noncurrent	$ 1,035	$ 62
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	15,000,000	15,000,000
Preferred Stock Shares Designated	5,000,000	5,000,000
Preferred Stock, shares issued	1,000,000	1,000,000
Preferred Stock, shares outstanding	1,000,000	1,000,000
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	100,000,000	100,000,000
Common Stock, shares issued	53,987,074	50,991,285
Common Stock, shares outstanding	53,987,074	50,991,285
Common Stock, Shares Subscribed but Unissued	259,813	158,015

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenue
Investment advisory	$ 833		$ 2,147
Other	14,406		24,321
Net revenue	63,834	$ 50,697	119,259	$ 95,379
Operating expenses
Cost of goods sold - product revenue	1,668	878	3,140	1,347
Research and development - licenses acquired	1	1,800	98	3,094
General and administrative	10,146	8,524	20,934	16,509
Underwriting costs	42	0	187	0
Loss from operations	88,431	73,890	179,342	136,149
Loss from operations	(24,597)	(23,193)	(60,083)	(40,770)
Other income (expenses)
Interest income	294	190	572	326
Interest expense and financing fee	(2,144)	(1,380)	(4,227)	(2,078)
Change in fair value of derivative liabilities	(6,866)	1,452	(7,931)	5,794
Change in fair value of subsidiary convertible note	(140)	(188)	110	(285)
Change in fair value of investments	(707)	157	(825)	(511)
Other loss	(118)	13	(112)	13
Total other income (expenses)	(9,681)	244	(12,413)	3,259
Loss before income taxes	(34,278)	(22,949)	(72,496)	(37,511)
Income tax expense	1,438	0	1,438	0
Net loss	(35,716)	(22,949)	(73,934)	(37,511)
Less: net loss attributable to non-controlling interests	(14,105)	(5,584)	(31,305)	(8,164)
Net loss attributable to common stockholders	$ (21,611)	$ (17,365)	$ (42,629)	$ (29,347)
Basic and diluted net loss per common share	$ (0.50)	$ (0.43)	$ (0.99)	$ (0.73)
Weighted average common shares outstanding basic and diluted	43,377,629	40,551,844	42,948,780	40,457,524
Parent Company [Member]
Revenue
Product revenue, net	$ 6,689	$ 4,054	$ 12,198	$ 6,139
Revenue - from a related party	126	350	520	1,043
Net revenue	6,815	4,404	12,718	7,182
Operating expenses
Cost of goods sold - product revenue	1,668	878	3,140	1,347
Research and development	17,488	11,683	42,446	18,793
Research and development - licenses acquired	1	1,800	98	3,094
General and administrative	13,056	11,134	26,604	21,386
Loss from operations	32,213	25,495	72,288	44,620
National Holdings Corporation [Member]
Revenue
Commissions	31,407	23,993	57,025	48,499
Net dealer inventory gains	2,929	2,366	5,119	4,877
Investment banking	11,037	10,592	23,741	17,653
Investment advisory	5,197	3,490	10,530	6,875
Interest and dividends	601	675	1,232	1,391
Transfer fees and clearing services	1,777	1,687	4,074	4,185
Tax preparation and accounting	3,868	3,144	4,391	4,000
Other	203	346	429	717
Net revenue	57,019	46,293	106,541	88,197
Operating expenses
Commissions, compensation and fees	49,345	41,762	92,906	79,020
Clearing fees	578	618	1,321	1,356
Communications	813	682	1,573	1,404
Occupancy	1,141	936	2,096	1,944
Licenses and registration	530	427	1,167	832
Professional fees	578	991	1,971	2,254
Interest	2	4	4	8
Depreciation and amortization	857	500	1,716	1,006
Other administrative expenses	2,332	2,475	4,113	3,705
Loss from operations	$ 56,218	$ 48,395	$ 107,054	$ 91,529

Condensed Consolidated Stateme5

Condensed Consolidated Statement of Changes in Stockholders' Equity - 6 months ended Jun. 30, 2018 - USD ($) $ in Thousands	Total	Series A Preferred Stock [Member]	Common Stock [Member]	Common Shares Issuable [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Non-Controlling Interests [Member]
Balance at Dec. 31, 2017	$ 120,502	$ 1	$ 51	$ 500	$ 364,148	$ (312,127)	$ 67,929
Balance (in shares) at Dec. 31, 2017		1,000,000	50,991,285
Stock-based compensation expense	8,623	$ 0	$ 0	0	8,623	0	0
Issuance of restricted stock	0	0	$ 2	0	(2)	0	0
Issuance of restricted stock (in shares)			1,558,274
Issuance of common stock under ESPP	128	$ 0	$ 0	0	128	0	0
Issuance of common stock under ESPP (in shares)		0	43,707
Issuance of subsidiaries' common shares for license expenses	23	$ 0	$ 0	0	23	0	0
Issuance of NHLD’s common shares for tax withholding	(82)	0	0	0	(82)	0	0
Subsidiary’s offering, net	22,657	0	0	0	22,657	0	0
Exercise of subsidiary's warrants for cash	181	0	0	0	181	0	0
Issuance of common stock for at-the-market offering	4,070	0	$ 1	0	4,069	0	0
Issuance of common stock for at-the-market offering (in shares)			1,130,835
At-the-market offering cost	(141)	0	$ 0	0	(141)	0	0
Common shares issuable 2017 Subordinated Note Financing interest expense	978	0	0	978	0	0	0
Common shares issued for 2017 Subordinated Note Financing interest expense	0	$ 0	$ 0	(989)	989	0	0
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)		0	262,973
Common shares issuable for Opus interest expense	287	$ 0	$ 0	287	0	0	0
Preferred A dividends declared and paid	(1,172)	0	0	0	(1,172)	0	0
Offering cost and financing fee paid to NHLD	1,297	0	0	0	1,297	0	0
Acquisition of business - NHLD	(767)	0	0	0	(767)	0	0
Warrant liability reclassification - NHLD	13,615	0	0	0	13,615	0	0
Non-controlling interest in subsidiaries	0	0	0	0	(15,708)	0	15,708
Net loss attributable to non-controlling interest	31,305	0	0	0	0	0	(31,305)
Net loss attributable to common stockholders	(42,629)	0	0	0	0	(42,629)	0
Balance at Jun. 30, 2018	$ 96,265	$ 1	$ 54	$ 776	$ 397,858	$ (354,756)	$ 52,332
Balance (in shares) at Jun. 30, 2018		1,000,000	53,987,074

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash Flows from Operating Activities:
Net Loss	$ (73,934)	$ (37,511)
Reconciliation of net loss to net cash used in operating activities:
Depreciation expense	831	543
Amortization of intangible asset	1,388	819
Amortization of debt discount	481	702
Amortization of product revenue license fee	266	267
Amortization of forgivable loans to registered representatives	310	362
Amortization of deferred clearing credit	(105)	(104)
Stock-based compensation expense	8,623	7,736
Recovery of doubtful accounts	(46)	(256)
Common shares issuable for 2017 Subordinated Note Financing interest expense	978	189
Common shares issuable for Opus interest expense	287	0
Change in fair value of investments	825	511
Change in fair value of derivative liabilities	7,931	(5,794)
Change in fair value of subsidiary convertible note	(110)	285
Research and development - licenses acquired, expense	98	3,095
Change in fair value of subsidiaries’ assets and liabilities	10	10
Increase (decrease) in cash and cash equivalents resulting from changes in operating assets and liabilities:
Accounts receivable	2,437	(1,506)
Receivables from broker-dealers and clearing organizations	(4,017)	544
Forgivable loans receivable	(292)	(47)
Securities owned, at fair value	(1,827)	(1,049)
Inventory	(128)	(96)
Other receivables - related party	(157)	185
Prepaid expenses and other current assets	(1,213)	(2,590)
Accounts payable and accrued expenses	1,154	(1,721)
Accounts payable and accrued expenses - related party	(99)	24
Securities sold, but not yet purchased, at fair value	(143)	(221)
Deferred revenue	650	0
Interest payable	256	3
Interest payable - related party	(3)	259
Other long-term liabilities	248	2
Net cash used in operating activities	(55,301)	(35,359)
Cash Flows from Investing Activities:
Purchase of research and development licenses	(75)	(665)
Purchase of property and equipment	(4,663)	(454)
Purchase of short-term investment (certificates of deposit)	(35,000)	(20,038)
Redemption of short-term investment (certificates of deposit)	36,002	0
Security deposits collected	(343)	0
Security deposits refund	0	3
Acquisition of business - National	(187)	(19)
Acquisition of intangible assets - National	(45)	0
Collection on notes receivable	47	8
Net cash used in investing activities	(4,264)	(21,165)
Cash Flows from Financing Activities:
Inter-company costs related to the issuance of Series A preferred stock	1,297	0
Payment of Preferred A dividends	(1,172)	0
Proceeds from at-the-market offering	4,070	0
Payment of cost related to at-the-market offering	(141)	0
Proceeds from subsidiaries' offering	23,011	93,853
Payment of costs related to subsidiaries' offering	(354)	(862)
Proceeds from exercise of subsidiary’s warrants	181	0
Proceeds from exercise of stock options	0	27
Proceeds from issuance of common stock under ESPP	128	42
Repurchase of NHLD common stock for tax withholding	(82)	0
Proceeds from NSC Note	0	18,967
Payment of debt issuance costs associated with NSC Note	0	(1,939)
Payment of debt issuance costs associated with 2017 Subordinated Note Financing	(404)	0
Proceeds from Opus Credit Facility	0	2,500
Proceeds from 2018 Venture Notes	21,707	0
Payment of debt issue costs associated with 2018 Venture Notes	(127)	0
Payment of debt issuance costs associated with subsidiaries’ Convertible Note	0	(4)
Payment of subsidiaries’ Convertible Note	(4,076)	0
Net cash provided by financing activities	44,038	112,584
Net (decrease) increase in cash and cash equivalents, cash deposits with clearing organizations and restricted cash	(15,527)	56,060
Cash and cash equivalents, cash deposits with clearing organizations and restricted cash at beginning of period	132,343	105,184
Cash and cash equivalents, cash deposits with clearing organizations and restricted cash at end of period	116,816	161,244
Supplemental disclosure of cash flow information:
Cash paid for interest	5	8
Supplemental disclosure of non-cash financing and investing activities:
Issuance of restricted stock	2	1
Issuance of warrants by subsidiary in conjunction with NSC debt	0	750
Issuance of warrants in conjunction with 2017 Subordinated Note Financing	0	1,197
Debt discount related to Opus Credit Facility	0	201
Unpaid debt offering cost	5	79
Conversion of subsidiaries notes payable	0	314
Common shares issuable for license acquired	0	1,682
Common shares issued for NHLD interest expense	990	0
Fixed assets (acquired but not paid)	818	0
Business acquired:
Business acquired	187	19
Reclassification of warrant liability from debt to equity	13,615	0
National [Member]
Supplemental disclosure of cash flow information:
Cash paid for interest	1,819	58
Cash paid for income taxes	630	576
Supplemental disclosure of non-cash financing and investing activities:
Fixed assets (acquired but not paid)	0	42
Related Party [Member]
Supplemental disclosure of cash flow information:
Cash paid for interest	$ 281	$ 0

Organization and Description of

Organization and Description of Business	6 Months Ended
	Jun. 30, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Organization and Description of Business	1. Organization and Description of Business Fortress Biotech, Inc. (“Fortress” or the “Company”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also referred to as the “Fortress Companies.” Additionally, the Company maintains a controlling interest in National Holdings Corporation, a diversified independent brokerage company (together with its subsidiaries, referred to as “NHLD” or “National”).One of National’s subsidiaries, National Securities Corporation (“NSC”), is an independent broker-dealer offering retail and institutional advisory, investment, insurance and tax planning services. From time to time, NSC provides services to the Company and its affiliates. In addition to its internal development programs, the Company leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. The Company and the Fortress Companies may seek licenses, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. As of June 30, 2018, in addition to National, the Company has several consolidated Fortress Companies, some of which contain product licenses, including: Aevitas Therapeutics, Inc. (“Aevitas”), Avenue Therapeutics, Inc. (“Avenue”), Caelum Biosciences, Inc. (“Caelum”), Cellvation, Inc. (“Cellvation”), Checkpoint Therapeutics, Inc. (“Checkpoint”), Cyprium Therapeutics, Inc. (“Cyprium”), Helocyte, Inc. (“Helocyte”), Journey Medical Corporation (“Journey” or “JMC”), Mustang Bio, Inc. ( “Mustang”), Tamid Bio, Inc. (“Tamid”) and JG Pharma, Inc., a subsidiary of JMC. The Company also has operational subsidiaries CB Securities Corporation (“CB Securities”), Immune Limited and FBIO Acquisition, Inc. (the acquisition vehicle the Company used to obtain National) and acquisition companies for which the Company is actively seeking product candidate licenses, including Coronado SO Co. (“Coronado SO”), Escala Therapeutics, Inc. (“Escala”), GeneXion Oncology, Inc. (“GeneXion”), Fortress Biotech China, Inc. (“Fortress China”), FBIO Acquisition Corp. IV and FBIO Acquisition Corps. VI - XIV. Liquidity and Capital Resources Since inception, the Company’s operations have been financed primarily through the sale of equity and debt securities and the proceeds from the exercise of warrants and stock options. The Company has incurred losses from operations and negative cash flows from operating activities since inception and expects to continue to incur substantial losses for the next several years as it continues to fully develop and prepare regulatory filings and obtain regulatory approvals for its existing and new product candidates. The Company’s current cash and cash equivalents are sufficient to fund operations for at least the next 12 months. However, the Company will need to raise additional funding through strategic relationships, public or private equity or debt financings, grants or other arrangements to fully develop and prepare regulatory filings and obtain regulatory approvals for the Company’s existing and new product candidates, fund operating losses, and, if deemed appropriate, establish or secure through third parties manufacturing for the Company’s potential products, sales and marketing capabilities. If such funding is not available or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure will be curtailed. The Company also has the ability, subject to limitations imposed by Rule 144 of the Securities Act of 1933 and other applicable laws and regulations, to raise money from the sale of common stock of the public companies in which it has

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of the Companies, Avenue, Checkpoint, Mustang and National. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2018, from which the Company derived the balance sheet data at December 31, 2017, as well as National’s Form 10-K and 10-K/A filed with the SEC on December 22, 2017 and January 17, 2018, respectively and their Form 10-Q, filed with the SEC on February 14, 2018, Checkpoint’s Form 10-K filed with the SEC on March 16, 2018, Mustang’s Form 10-K, filed with the SEC on March 29, 2018, and Avenue’s Form 10-K, filed with the SEC on March 1, 2018. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Avenue, Aevitas, Caelum, CB Securities, Cellvation, Coronado SO, Checkpoint, Cyprium, Escala, GeneXion, Helocyte, Immune Limited, JMC, Mustang, NHLD, Tamid, Coronado SO, Escala, Fortress China, FBIO Acquisition Corp. IV, FBIO Acquisition Corps. VI – XIV, and JG Pharma, Inc., a subsidiary of JMC. All intercompany balances and transactions have been eliminated. The National assets acquired, and liabilities assumed, and revenues and expenses are reported on a one quarter lag. Therefore, the National assets acquired, and liabilities assumed included in these condensed consolidated financial statements as of June 30, 2018 are actually the assets and liabilities as of March 31, 2018 and the revenues and expenses included in these condensed consolidated financial statements for the quarter ending June 30, 2018 are actually the revenues and expenses for the quarter ending March 31, 2018. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, revenue with customers, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates. There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Form 10-K filed with the SEC on March 16, 2018, with the exception of revenue recognition. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09) as modified by ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, and ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” 0.1 The new revenue guidance does not apply to revenue associated with financial instruments, including National’s warrants and securities that are accounted for under other U.S. GAAP, and as a result, did not have an impact on the elements of the Company’s Condensed Consolidated Statements of Operations most closely associated with financial instruments. The new revenue standard primarily impacts the following of the revenue recognition and presentation accounting policies: ⋅ Investment Banking Revenues ⋅ Investment Banking Advisory Expenses ⋅ Investment Banking Underwriting and Advisory Expenses The new revenue standard requires enhanced disclosures, which are included in Note 21 to the Company’s condensed consolidated financial statements for the three months ended June 30, 2018. Contract Assets Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer, excluding unconditional rights to consideration that are presented as receivables. Contract Liabilities Contract liabilities represent the Company’s obligation to deliver products or provide data to customers in the future for which cash has already been received. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting

National Holdings Corporation A

National Holdings Corporation Acquisition - Intangible Assets	6 Months Ended
	Jun. 30, 2018
Business Combinations [Abstract]
National Holdings Corporation Acquisition - Intangible Assets	3. National Holdings Corporation Acquisition - Intangible Assets Useful life Trademark 10 years Customer lists 6 years Software license 3 years Intangible assets at December 31, 2017 $ 14,340 Addition 45 Amortization expense (1,388) Intangible assets at June 30, 2018 $ 12,997 Trademark Customer Software Total Six Months Ended December 31, 2018 $ 151 $ 1,261 $ 10 $ 1,422 Year Ended December 31, 2019 300 2,500 15 2,815 Year Ended December 31, 2020 301 2,506 15 2,822 Year Ended December 31, 2021 300 2,500 5 2,805 Year Ended December 31, 2022 300 1,726 - 2,026 Thereafter 1,107 — - 1,107 Total $ 2,459 $ 10,493 $ 45 $ 12,997 The Company reviews its finite-lived intangible assets for impairment when events or changes in circumstances indicate that the carrying amount of a finite-lived intangible asset may not be recoverable. Recoverability of a finite-lived intangible asset is measured by a comparison of its carrying amount to the undiscounted future cash flows expected to be generated by the asset. If the asset is considered to be impaired, the impairment recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were no indicators of impairment during the six months ended June 30, 2018.

Broker-Dealers and Clearing Org

Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities	6 Months Ended
	Jun. 30, 2018
Brokers and Dealers [Abstract]
Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities	4. Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities At March 31, 2018 and September 30, 2017, National’s receivables of $ 11.4 7.4 6.0 5.2 0.5 0.5

Forgivable Loans Receivable

Forgivable Loans Receivable	6 Months Ended
	Jun. 30, 2018
Forgivable Loans Receivable [Abstract]
Forgivable Loans Receivable	5. Forgivable Loans Receivable From time to time, National’s operating subsidiaries may make loans, evidenced by promissory notes, primarily to newly recruited independent financial advisors as an incentive for their affiliation. The notes receivable balance is comprised of unsecured non-interest-bearing and interest-bearing loans (weighted average interest rate of 4 0.3 0.4 National provides an allowance for doubtful accounts on the notes based on historical collection experience and continually evaluates the receivables for collectability and possible write-offs where a loss is deemed probable. As of March 31, 2018 and September 30, 2017, no allowance for doubtful accounts was required. There were no unamortized forgivable loans outstanding at March 31, 2018 and September 30, 2017 attributable to registered representatives who ended their affiliation with National’s subsidiaries prior to the fulfillment of their obligation.

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment Estimated Useful June 30, December 31, Computer equipment 3 $ 648 $ 543 Furniture and fixtures 5 1,128 1,009 Machinery and equipment 5 1,897 143 Leasehold improvements 5 – 15 9,181 5,351 Construction in process (1) N/A 864 1,241 Total property and equipment 13,718 8,287 Less: accumulated depreciation (1,674) (1,171) Property and equipment, net $ 12,044 $ 7,116 (1) Relates to the Mustang cell processing facility. Fortress's depreciation expense for the three months ended June 30, 2018 and 2017, was approximately $ 0.3 0.2 0.5 0.4 Estimated Useful March 31, September 30, Equipment 5 $ 1,344 $ 1,306 Furniture and fixtures 5 291 284 Leasehold improvements Lesser of useful life or term 1,011 1,006 Capital Leases (primarily composed of computer equipment) 5 276 276 Fixed assets – gross 2,922 2,872 Accumulated depreciation and amortization (803) (475) Fixed asset - net $ 2,119 $ 2,397 National's depreciation expense for the three months ended March 31, 2018 and 2017, was approximately $ 0.2 0.1 0.3 0.2

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	7. Fair Value Measurements Certain of the Company’s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to their liquid or short-term nature, such as accounts payable, accrued expenses and other current liabilities. Origo Acquisition Corporation A shareholder meeting of “Origo Acquisition Corporation” (“Origo”) was held on June 12, 2018, at which the Origo shareholders approved the extension of the date by which to consummate a business combination from June 12, 2018 to September 12, 2018. As of June 30, 2018, the Company valued its investment in Origo, a publicly traded company, utilizing the following assumptions: probability of a successful business combination of 13.93 1.80 0.18 0.30 0.8 0.6 0.3 Securities Owned National The fair value of National’s warrants, representing the cumulative value of warrants received in publicly traded companies that are not related parties, in which NSC as placement agent received warrants as the placement agent. National calculated the fair value of the warrants using a Black Scholes model. March 31, 2018 Risk-free interest rate 1.63% – 2.56% Expected dividend yield –% Expected term in years 0.18 – 4.11 Remaining volatility 56.4% – 386.1% Strike price $0.01 – $10.00 ($ in thousands) Fair Value of Beginning balance at September 30, 2017 $ 202 Trading revenue gain 1,349 Ending balance at March 31, 2018 $ 1,551 Warrant Liabilities Helocyte 0 0 ($ in thousands) Fair Value of Beginning balance at January 1, 2018 $ 87 Change in fair value of derivative liabilities (87) Ending balance at June 30, 2018 $ – Notes at Fair Value Helocyte Helocyte’s convertible note is measured at fair value using the Monte Carlo simulation valuation methodology. ($ in thousands) Helocyte Beginning balance at January 1, 2018 $ 4,700 Payment of convertible notes (4,076) Change in fair value of convertible notes (291) Ending balance at June 30, 2018 $ 333 Caelum June 30, 2018 Risk-free interest rate 1.89%- 2.37 % Expected dividend yield - % Expected term in years 0.21 – 1.21 Expected volatility 53.0 % ($ in thousands) Caelum Beginning balance at January 1, 2018 $ 10,059 Change in fair value of convertible notes 181 Ending balance at June 30, 2018 $ 10,240 The following tables classify the fair value hierarchy of Fortress's financial instruments, exclusive of National's financial instruments, measured at fair value as of June 30, 2018 and December 31, 2017: Fair Value Measurement as of June 30, 2018 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 565 $ 565 Total $ - $ - $ 565 $ 565 Liabilities Warrant liabilities $ - $ - $ - $ - Helocyte Convertible Note, at fair value - - 333 333 Caelum Convertible Note, at fair value - - 10,240 10,240 Total $ - $ - $ 10,573 $ 10,573 Fair Value Measurement as of December 31, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ – $ – $ 1,390 $ 1,390 Total $ – $ – $ 1,390 $ 1,390 Liabilities Warrant liabilities $ – $ – $ 87 $ 87 Caelum Convertible Note, at fair value – – 10,059 10,059 Helocyte Convertible Note, at fair value – – 4,700 4,700 Total $ – $ – $ 14,846 $ 14,846 Fair Value Measurement as of March 31, 2018 Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 32 $ – $ – $ 32 Municipal bonds – 1,183 – 1,183 Restricted stock – 1,046 – 1,046 Warrants – - 1,551 1,551 Total $ 32 $ 2,229 $ 1,551 $ 3,812 Liabilities National Securities sold, but not yet purchased at fair value: Corporate stocks 2 – – 2 Corporate debt – 6 – 6 Contingent consideration – – 889 889 Total $ 2 $ 6 $ 889 $ 897 Fair Value Measurement as of September 30, 2017 Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 116 $ – $ – $ 116 Municipal bonds – 1,239 – 1,239 Restricted stock – 82 – 82 Warrants – – 548 548 Total $ 116 $ 1,321 $ 548 $ 1,985 Liabilities National Securities sold, but not yet purchased at fair value Municipal bonds – 151 – 151 Contingent consideration – – 311 311 Warrants issued - National – – 5,597 5,597 Total $ – $ 151 $ 5,908 $ 6,059 Warrants issued - National On March 15, 2018, National, Computershare Inc., a Delaware corporation (“Computershare”), and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company (and together with Computershare, the “Warrant Agent”) agreed to amend and restate the terms of the form of warrant agreement dated December 13, 2016 (the “Original Agreement”). The Amended and Restated Warrant Agreement (the “Amended Agreement”) explicitly provides that National shall not be required to pay cash if it cannot issue registered shares of Common Stock upon exercise of a Warrant and as such meeting the criteria for equity classification. 44 13.6 March 15, 2018 Dividend yield – % Expected volatility 59.23 % Risk-free interest rate 2.42 % Life (in years) 3.49 % ($ in thousands) National’s Beginning balance at September 30, 2017 $ 5,597 Change in fair value of derivative liability 8,018 Ending balance at March 15, 2018 13,615 Reclassification of warrant to equity (13,615) Ending balance at March 31, 2018 $ – National listed the warrants on the Nasdaq Capital Market under the symbol “NHLDW” in February 2017. ($ in thousands) Investment in Helocyte Caelum Warrants Warrant Total Balance at December 31, 2017 $ 1,390 $ 4,700 $ 10,059 $ 5,597 $ 87 $ 21,833 Payment of convertible note - (4,076) - - - (4,076) Reclassification of warrant liability from debt to equity - - - (13,615) - (13,615) Change in fair value of investments (825) - - - - (825) Change in fair value of convertible notes - (291) 181 - - (110) Change in fair value of derivative liabilities - - - 8,018 (87) 7,931 Balance at June 30, 2018 $ 565 $ 333 $ 10,240 $ 0 $ 0 $ 11,138 For the six months ended June 30, 2018, no transfers occurred between Level 1, Level 2 and Level 3 instruments.

Licenses Acquired

Licenses Acquired	6 Months Ended
	Jun. 30, 2018
Licenses Acquired [Abstract]
Licenses Acquired	8. Licenses Acquired In accordance with ASC 730-10-25-1, Research and Development, For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 Fortress $ – $ 300 $ – $ 300 Fortress Companies: Checkpoint – – – 400 Helocyte – – 21 – Mustang – 1,500 75 2,075 Cellvation – – 1 – Caelum – – – 219 Cyprium – – – 100 Aevitas 1 – 1 – Total $ 1 $ 1,800 $ 98 $ 3,094 Checkpoint For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 Jubliant Biosys License CK-103 $ – $ – $ – $ 400 Total Licenses Acquired Expense $ – $ – $ – $ 400 See Note 21 for revenue recognized in connection with the Jubilant license under a sublicense agreement with TGTX, a related party. Mustang For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 City of Hope (COH) IL-13 License $ – $ – $ – $ 250 COH IV/ICV License – – – 125 COH HER2 License – 600 – 600 COH CS-1 License – 600 – 600 COH License for PSCA – 300 – 500 Manufacturing License – – 75 – Total licenses acquired expense $ – $ 1,500 $ 75 $ 2,075 Caelum For the three and six months ended June 30, 2018 and 2017, respectively, Caelum recorded expense of approximately $ 0 0 0 0.2 Cyprium For the three and six months ended June 30, 2018 and 2017, respectively, Cyprium recorded expense of approximately $ 0 0 0 0.1 Eunice Kennedy Shriver

Sponsored Research and Clinical

Sponsored Research and Clinical Trial Agreements	6 Months Ended
	Jun. 30, 2018
Research and Development [Abstract]
Research, Development, and Computer Software Disclosure	9. Sponsored Research and Clinical Trial Agreements Aevitas On January 25, 2018, Aevitas entered into a Sponsored Research Agreement with the University of Massachusetts (“UMass SRA”) for certain continued research and development activities related to the development of adeno-associated virus (“AAV”) gene therapies in complement-mediated diseases. The total amount to be funded by Aevitas under the UMass SRA is $ 0.8 0.8 0.4 Caelum On March 12, 2018, Caelum entered into a Sponsored Research Agreement with Columbia University to conduct preclinical research in connection with CAEL 101. The total cost of the study approximates $ 0.1 27,000 38,000 Cellvation For the three and six months ended June 30, 2018 and 2017, respectively, Cellvation recorded expense of $ 0.1 0.2 0.1 0.2 Checkpoint In connection with its license agreement with NeuPharma, Inc. (“NeuPharma”), Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities and subsequently entered into an agreement with TGTX, a related party, to assume all costs associated with this Sponsored Research Agreement, including all amounts previously paid by the Company. For the three and six months ended June 30, 2018 and 2017, approximately $ 0 31,000 0.2 0.4 Helocyte For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 COH Triplex clinical research and support $ – $ 535 $ – $ 1,035 COH PepVax clinical research and support – – – 235 COH Pentamer clinical research and support 204 12 204 12 Total licenses acquired expense $ 204 $ 547 $ 204 $ 1,282 During the first quarter of 2018, Helocyte elected to discontinue the further development of its HLA-restricted, single-antigen PepVax program and as such will cease to incur costs associated with this program. Mustang For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 COH CAR T $ 500 $ 500 $ 1,000 $ 1,000 COH - CD123 114 575 264 595 COH - IL13Ra2 143 1,001 503 1,010 City of Hope – Manufacturing 115 – 229 – Fred Hutch - CD20 418 – 684 – Total $ 1,290 $ 2,076 $ 2,680 $ 2,605 See Note 21 for revenue recognized in connection with its sponsored research agreement with Neupharma under a sublicense agreement with TGTX, a related party. Tamid On November 30, 2017, in connection with its three separate license agreements with UNC, Tamid entered into a Sponsored Research Agreement with UNC (“UNC SRA”) for certain continued research and development activities related to Nanodysferlin for treatment of Dysferlinopathy, and AAV-HLA-G for ocular diseases. Total amount to be funded by Tamid under the UNC SRA is $ 2.3 0.8 0.2 0.4

Intangibles, net

Intangibles, net	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles, net	10. Intangibles, net Journey Pursuant to the terms of Journey’s license agreements for its branded products, Journey made upfront payments totaling $ 1.6 0.1 0.1 0.3 0.3

Debt and Interest

Debt and Interest	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Debt and Interest	11. Debt and Interest Debt 2018 Venture Notes During the period ended March 31, 2018, the Company closed a private placement of promissory notes for an aggregate of $ 21.7 The notes mature 36 months from issuance, provided that during the first 24 months the Company may extend the maturity date by six months. 8 NSC acted as the sole placement agent for the 2018 Venture Notes. The Company paid NSC a fee of $ 1.7 The 2018 Venture Notes allows the Company to transfer a portion of the proceeds from the 2018 Venture Notes to a Fortress subsidiary upon the completion by such subsidiary of an initial public offering in which it raises sufficient equity capital so that it has cash equal to five times the amount of the portion of the proceeds of the 2018 Venture Notes so transferred (the “SubCo Funding Threshold”). At the time of transfer the Company’s obligation under the NSC Note will be reduced by the amount transferred. During the six months ended June 30, 2018, the Company has transferred $ 1.4 1.1 1.0 1.2 In connection with this transfer NSC will receive warrants to purchase each such subsidiary’s stock equal to 25 10 Opus Credit Facility Agreement Maturity Date Extension On March 12, 2018, the Company and Opus Point Healthcare Innovation Healthcare Fund (“OPHIF”) amended and restated the Opus Credit Facility (the “A&R Opus Credit Facility”). The A&R Opus Credit Facility extended the maturity date of the notes issued under the Opus Credit Facility from September 14, 2018 September 14, 2019 12 ($ in thousands) June 30, December 31, Interest Rate Maturity IDB Note $ 14,929 $ 14,929 2.25 % August - 2020 2017 Subordinated Note Financing 3,254 3,254 8.00 % March - 2020 2017 Subordinated Note Financing 13,893 13,893 8.00 % May - 2020 2017 Subordinated Note Financing 1,820 1,820 8.00 % June - 2020 2017 Subordinated Note Financing 3,017 3,018 8.00 % August - 2020 2017 Subordinated Note Financing 6,371 6,371 8.00 % September - 2020 2018 Venture Notes 6,517 – 8.00 % February - 2021 2018 Venture Notes 15,190 – 8.00 % March - 2021 Opus Credit Facility 9,500 9,500 12.00 % September - 2019 Helocyte Convertible Note, at fair value – 1,000 8.00 % December - 2017 Helocyte Convertible Note, at fair value 300 2,194 8.00 % September - 2018 Helocyte Convertible Note, at fair value – 1,062 8.00 % April - 2018 Helocyte Convertible Note, at fair value 23 444 8.00 % November - 2018 Helocyte Convertible Note, at fair value – – 8.00 % September - 2018 Helocyte Convertible Note, at fair value 10 – 8.00 % October - 2018 Caelum Convertible Note, at fair value 1,036 1,017 8.00 % January - 2019 Caelum Convertible Note, at fair value 7,024 6,900 8.00 % February - 2019 Caelum Convertible Note, at fair value 2,180 2,142 8.00 % March - 2019 Total notes payable 85,064 67,544 Less: Discount on notes payable 1,035 1,035 Total notes payable $ 84,029 $ 66,509 Interest Expense Three Months Ended June 30, Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 IDB Note Interest $ 85 $ 87 $ 169 $ 169 Total IDB Note 85 87 169 169 NSC Debt Interest – 84 – 155 Amortization of fees – 40 – 73 Total NSC Debt – 124 – 228 2017 Subordinated Note Financing Interest 1,049 406 2,097 406 Amortization of fees 30 175 51 175 Total 2017 Subordinated Note Financing 1,079 581 2,148 581 Opus Credit Facility Interest 284 276 565 508 Amortization of fees 101 241 420 454 Total Opus Note 385 517 985 962 2018 Venture Notes Interest 429 – 485 – Amortization of fees 9 – 10 – Total 2018 Venture Notes 438 – 495 – LOC Fees Interest 9 7 16 15 Total LOC 9 7 16 15 Helocyte Convertible Note Interest 19 57 87 111 Financing fee – – – 1 Total Helocyte Convertible Note 19 57 87 112 Avenue Convertible Note Interest – 5 – 5 Financing fee – - – 3 Total Avenue Convertible Note – 5 – 8 Caelum Convertible Note Interest 195 – 391 – Total Caelum Convertible Note 195 – 391 – Falk CSR Interest (66) – (64) – Total Falk CSR (66) – (64) – D&O Insurance Interest – 2 – 3 Total D&O Insurance – 2 – 3 Total Interest Expense and Financing Fee $ 2,144 $ 1,380 $ 4,227 $ 2,078

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	6 Months Ended
	Jun. 30, 2018
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	12. Accrued Expenses and Other Long-Term Liabilities June 30, December 31, Accrued Expenses: Professional fees $ 1,535 $ 1,625 Salaries, bonuses and related benefits 3,569 5,279 Accrued expenses - related party 73 95 Research and development 5,143 4,046 Dr. Falk Pharma milestone (See Note 16) 3,365 3,059 Accrued royalties payable 1,268 1,411 Deferred coupon funding 1,777 1,087 Other 779 1,030 Total accrued expenses $ 17,509 $ 17,632 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 4,987 4,739 Total other long-term liabilities $ 4,987 $ 4,739 March 31, 2018 September 30, 2017 Legal $ 615 $ 877 Audit 299 176 Telecommunications 194 205 Data Services 526 464 Regulatory 638 540 Settlements 1,703 2,403 Deferred rent 686 497 Other 2,903 3,242 Total $ 7,564 $ 8,404

Non-Controlling Interests

Non-Controlling Interests	6 Months Ended
	Jun. 30, 2018
Noncontrolling Interest [Abstract]
Non-Controlling Interests	Non-Controlling Interests As of June 30, 2018 NCI Equity Share Net gain/(loss) attributable Non-controlling interests Non- Aevitas $ (407) $ (184) $ (591) 37.0 % Avenue 2 12,865 (9,631) 3,234 64.5 % Caelum (2,121) (1,474) (3,595) 33.9 % Cellvation (418) (91) (509) 21.6 % Checkpoint 1 24,543 (9,482) 15,061 67.5 % Coronado SO (290) - (290) 13.0 % Cyprium (183) (50) (233) 10.8 % Helocyte (3,203) (91) (3,294) 19.8 % JMC (459) 165 (294) 6.3 % Mustang 2 37,669 (6,729) 30,940 60.0 % National Holdings 15,805 (3,628) 12,177 43.4 % Tamid (164) (110) (274) 24.0 % Total $ 83,637 $ (31,305) $ 52,332 As of December 31, 2017 NCI Equity Share Net gain/(loss) attributable Non-controlling interests Non- Aevitas $ (126) $ (168) $ (294) 35.4 % Avenue 2 17,454 (4,646) 12,808 66.1 % Caelum (815) (1,262) (2,077) 34.7 % Cellvation (259) (96) (355) 21.5 % Checkpoint 1 21,635 (12,314) 9,321 62.0 % Coronado SO (236) (54) (290) 13.0 % Cyprium (143) (15) (158) 11.1 % Helocyte (1,907) (1,193) (3,100) 20.0 % JMC (469) 7 (462) 6.3 % Mustang 2 48,740 (11,911) 36,829 61.6 % National Holdings 17,021 (1,216) 15,805 43.4 % Tamid (6) (92) (98) 24.0 % Total $ 100,889 $ (32,960) $ 67,929 (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. (2) Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Net Loss Per Common Share	14. Net Loss per Common Share Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares of common stock outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock and common stock equivalents outstanding for the period. The Company’s common stock equivalents, including unvested restricted stock, options, and warrants have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted net loss per share is the same. Six Months Ended June 30, 2018 2017 Warrants to purchase Common Stock 894,189 603,316 Opus warrants to purchase Common Stock 1,880,000 1,880,000 Options to purchase Common Stock 1,085,502 1,101,193 Convertible Preferred Stock 1,000,000 - Unvested Restricted Stock 11,023,682 9,864,417 Unvested Restricted Stock Units 1,864,980 1,258,372 Total 17,748,353 14,707,298

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Jun. 30, 2018
Stockholders' Equity Note [Abstract]
Stockholders’ Equity	Stockholders’ Equity Stock-based Compensation For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 Employee Awards $ 1,121 $ 1,150 $ 2,063 $ 2,424 Executive awards of Fortress Companies’ stock 444 540 962 1,096 Non-employee awards 23 23 46 36 Fortress Companies: Avenue 322 19 671 24 Checkpoint 72 2,382 1,209 3,362 Mustang 972 397 2,966 397 Other 198 113 30 213 National 418 183 676 184 Total stock-based compensation $ 3,570 $ 4,807 $ 8,623 $ 7,736 For the three months ended June 30, 2018 and 2017, approximately $ 0.8 2.4 2.8 2.4 For the six months ended June 30, 2018 and 2017, approximately $ 3.1 3.2 5.5 4.3 Stock Options Number of Weighted Total weighted Weighted average Options vested and expected to vest at December 31, 2017 1,110,501 $ 3.78 $ 1,351,080 3.95 Exercised – – – – Options vested and expected to vest at June 30, 2018 1,110,501 $ 3.78 $ 719,324 3.46 Options vested and exercisable 1,085,501 $ 3.75 $ 719,324 3.43 As of June 30, 2018, Fortress had no unrecognized stock-based compensation expense related to options. Restricted Stock and Restricted Stock Units Number of Shares Weighted average Unvested balance at December 31, 2017 11,874,034 $ 2.63 Restricted stock granted 1,392,856 3.99 Restricted stock vested (213,333) 2.76 Restricted stock units granted 405,000 4.18 Restricted stock units forfeited (95,000) 3.49 Restricted stock units vested (130,584) 3.45 Unvested balance at June 30, 2018 13,232,973 $ 2.80 As of June 30, 2018, and 2017, the Company had unrecognized stock-based compensation expense related to restricted stock and restricted stock unit awards of approximately $ 12.4 2.7 2.9 2.3 Warrants Number of Weighted Total weighted Weighted average Outstanding as of December 31, 2017 2,774,189 $ 3.30 $ 2,204,530 4.47 Granted – – – – Forfeited – – – – Outstanding as of June 30, 2018 2,774,189 $ 3.30 $ 96,600 3.97 Exercisable as of June 30, 2018 869,189 $ 3.96 $ 96,600 3.56 Employee Stock Purchase Plan Eligible employees can purchase the Company’s Common Stock at the end of a predetermined offering period at 85 As of June 30, 2018, 289,359 110,641 43,000 40,000 81,000 75,000 Capital Raises Fortress At the Market Offering Pursuant to the terms of the Company’s Amended and Restated At Market Issuance Sales Agreement, or Sales Agreement, with B. Riley FBR, Inc. (“B. Riley,” f/k/a MLV & Co. LLC, and FBR Capital Markets & Co.) (the “ATM”), for the six month period ended June 30, 2018, the Company issued 1,130,835 3.60 4.1 71,000 Fortress Companies Checkpoint Therapeutics, Inc. Checkpoint Public Offering of Common Stock On March 12, 2018, Checkpoint closed an underwritten public offering in which it sold 5,290,000 4.35 23.0 20.8 2.2 77.0

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Indemnification In accordance with its certificate of incorporation, bylaws and indemnification agreements, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Legal Proceedings – Fortress In the ordinary course of business, the Company and its subsidiaries may be subject to both insured and uninsured litigation. Suits and claims may be brought against the Company by customers, suppliers, partners and/or third parties (including tort claims for personal injury arising from clinical trials of the Company’s product candidates and property damage) alleging deficiencies in performance, breach of contract, etc., and seeking resulting alleged damages. Dr. Falk Pharma, GmbH v. Fortress Biotech, Inc. (Frankfurt am Main Regional Court, Ref. No. 3-06 0 28/16). Dr. Falk Pharma, GmbH (“Dr. Falk Pharma”) and Fortress were among the parties to that certain Collaboration Agreement dated March 20, 2012, whereby they agreed to collaborate to develop a product for treatment of Crohn’s disease. A dispute arose between Dr. Falk Pharma and Fortress with respect to their relative rights and obligations under the Collaboration Agreement; specifically, Dr. Falk Pharma contended that it had fulfilled its contractual obligations to Fortress and is entitled to the final milestone payment due under the Collaboration Agreement - EUR 2.5 million. Fortress contended that no such payment is due because a condition of the EUR 2.5 million payment was the delivery of a Clinical Study Report that addressed the primary and secondary objectives of a Phase II trial, and Fortress contended that Dr. Falk Pharma failed to deliver such a Clinical Study Report. Dr. Falk Pharma filed a lawsuit against Fortress in the above-referenced Court in Frankfurt, Germany to recover the EUR 2.5 million plus interest and attorneys’ fees, and Fortress filed an answer to the complaint, denying that it had any liability to Dr. Falk Pharma. 2.5 3.3 37,000 Litigation and Regulatory Matters - National National is a defendant or respondent in various pending and threatened arbitrations, administrative proceedings and lawsuits seeking compensatory damages. Several cases have no stated alleged damages. Claim amounts are infrequently indicative of the actual amounts National will be liable for, if any. Further, National has a history of collecting amounts awarded in these types of matters from its brokers that are still affiliated, as well as from those that are no longer affiliated. Many of these claimants also seek, in addition to compensatory damages, punitive or treble damages, and all seek interest, costs and fees. These matters arise in the normal course of business. National intends to vigorously defend itself in these actions, and the ultimate outcome of these matters cannot be determined at this time. Liabilities for potential losses from complaints, legal actions, government investigations and proceedings are established where the National believes that it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. In making these decisions, management bases its judgments on its knowledge of the situations, consultations with legal counsel and its historical experience in resolving similar matters. In many lawsuits, arbitrations and regulatory proceedings, it is not possible to determine whether a liability has been incurred or to estimate the amount of that liability until the matter is close to resolution. However, accruals are reviewed regularly and are adjusted to reflect the National’s estimates of the impact of developments, rulings, advice of counsel and any other information pertinent to a particular matter. Because of the inherent difficulty in predicting the ultimate outcome of legal and regulatory actions, management cannot predict with certainty the eventual loss or range of loss related to such matters. At March 31, 2018 and September 30, 2017, the National accrued approximately $ 1.7 2.4 0.4 1.0 0.7 1.0 0.0 0.3 0.3 0.8

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Note	Related Party Transactions Other Related Parties The Company’s Chairman, President and Chief Executive Officer, individually and through certain trusts over which he has voting and dispositive control, beneficially owned approximately 13.7 16.0 National Holdings Corporation The Company maintains a controlling interest in National Holdings Corporation, a diversified independent brokerage company. One of National’s subsidiaries, National Securities Corporation, is an independent broker-dealer offering retail and institutional advisory, investment, insurance and tax planning services. From time to time, NSC provides services to the Company and its affiliates. Shared Services Agreement with TGTX TGTX and the Company entered into an arrangement to share the cost of certain research and development employees. The Company’s Executive Vice Chairman, Strategic Development, is Executive Chairman and Interim Chief Executive Officer of TGTX. Under the terms of the Agreement, TGTX will reimburse the Company for the salary and benefit costs associated with these employees based upon actual hours worked on TGTX related projects. For the three months ended June 30, 2018 and 2017, the Company invoiced TGTX $ 0.7 0.4 1.0 0.6 0.4 Desk Space Agreements with TGTX and OPPM In connection with the Company’s Desk Space Agreements with TGTX and Opus Point Partners Management, LLC (“OPPM”), as of June 30, 2018, the Company had paid $ 0.6 42,000 96,000 43,000 10,000 0 94,000 Opus Credit Facility On March 12, 2018, the Company and OPHIF amended and restated the Opus Credit Facility (the “A&R Opus Credit Facility”). The A&R Opus Credit Facility extends the maturity date of the notes issued under the Opus Credit Facility from September 14, 2018 by one year to September 14, 2019. The A&R Opus Credit Facility also permits the Company to make portions of interest and principal repayments in the form of shares of the Company’s common stock and/or in common stock of the Company’s publicly-traded subsidiaries, subject to certain conditions. Fortress retains the ability to prepay the Notes at any time without penalty. The notes payable under the A&R Opus Credit Facility continue to bear interest at 12 0.3 0.5 Checkpoint Public Offering of Common Stock NSC, a subsidiary of National (of which the Company owns 56.3 NSC received a fee of approximately $1.8 million, or 8% on the gross proceeds raised of $23.0 million. The fees were eliminated in consolidation. Mustang Option on Collaboration Agreement with TGTX On February 2, 2018, Mustang entered into an Option Agreement the (“TGTX Mustang Option”) with TG Therapeutics, Inc. (“TGTX”), a related party, whereby TGTX was granted the option to enter into a global collaboration on the joint development and commercialization of product candidates pertaining to Mustang’s CD20 license agreement with the Fred Hutchinson Cancer Research Center. In consideration of the TGTX Mustang Option, TGTX paid an option fee of $ 50,000 2018 Venture Notes For the six-month period ended March 31, 2018, the Company raised approximately $ 21.7 1.7 Founders Agreement Fortress Company Effective Date (1) PIK Dividend as a % of Class of Stock Issued Helocyte March 20, 2015 2.5 % Common Stock Avenue February 17, 2015 2.5 % Common Stock Mustang March 13, 2015 2.5 % Common Stock Checkpoint March 17, 2015 0.0 % (2) Common Stock Cellvation October 31, 2016 2.5 % Common Stock Caelum January 1, 2017 2.5 % Common Stock Cyprium March 13, 2017 2.5 % Common Stock Aevitas July 28, 2017 2.5 % Common Stock Tamid November 30, 2017 (3) 2.5 % Common Stock (1) Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement. (2) Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5 (3) Represents the Trigger Date. Management Services Agreements The Company has entered in Management Services Agreements (the “MSAs”) with certain of its subsidiaries as described in the Company’s Form 10-K for the year ended December 31, 2017, filed with the SEC on March 16, 2018. Fortress Company Effective Date Annual MSA Fee (Income)/Expense Helocyte March 20, 2015 $ 500 Avenue (1) February 17, 2015 500 Mustang March 13, 2015 500 Checkpoint March 17, 2015 500 Cellvation October 31, 2016 500 Caelum January 1, 2017 500 Cyprium March 13, 2017 500 Aevitas July 28, 2017 500 Tamid November 30, 2017 500 Fortress (4,500) Consolidated (Income)/Expense $ – National On June 12, 2018, Michael S. Weiss, the Company’s Executive Vice Chairman, Strategic Development, retired from his position on the National board of directors. As of June 30, 2018, the Company owns approximately 56.3% of National. Additionally, the Company’s Chairman, President and Chief Executive Officer and the Company’s Executive Vice Chairman, Strategic Development are both Co-Portfolio Managers and Partners of OPPM, which owns approximately [ 4.6

Net Capital Requirements of Bro

Net Capital Requirements of Broker-Dealer Subsidiaries	6 Months Ended
	Jun. 30, 2018
Brokers and Dealers [Abstract]
Net Capital Requirements of Broker-Dealer Subsidiaries	Net Capital Requirements of Broker-Dealer Subsidiaries NSC is subject to the SEC’s Uniform Net Capital Rule (Rule 15c3-1) (the “Rule”), which, among other things, requires the maintenance of minimum net capital. At March 31, 2018, National Securities had net capital of $ 11.9 10.9 1,000,000 Advances, dividend payments and other equity withdrawals from the Company’s broker-dealer subsidiaries are restricted by the regulations of the SEC, and other regulatory agencies. These regulatory restrictions may limit the amounts that a subsidiary may dividend or advance to the Company.

Off Balance Sheet Risk and Conc

Off Balance Sheet Risk and Concentrations of Credit Risk	6 Months Ended
	Jun. 30, 2018
Risks and Uncertainties [Abstract]
Off Balance Sheet Risk and Concentrations of Credit Risk	Off Balance Sheet Risk and Concentrations of Credit Risk National is engaged in trading and providing a broad range of securities brokerage and investment services to a diverse group of retail and institutional clientele, as well as corporate finance and investment banking services to corporations and businesses. Counterparties to National’s business activities include broker-dealers and clearing organizations, banks and other financial institutions. National uses clearing brokers to process transactions and maintain customer accounts for National on a fee basis. National permits the clearing firms to extend credit to its clientele secured by cash and securities in the client’s account. National’s exposure to credit risk associated with the non-performance by its customers and counterparties in fulfilling their contractual obligations can be directly impacted by volatile or illiquid trading markets, which may impair the ability of customers and counterparties to satisfy their obligations to National. National has agreed to indemnify the clearing brokers for losses they incur while extending credit to National’s clients. It is National’s policy to review, as necessary, the credit standing of its customers and counterparties. Amounts due from customers that are considered uncollectible by the clearing broker are charged back to National by the clearing broker when such amounts become determinable. Upon notification of a charge back, such amounts, in total or in part, are then either (i) collected from the customers, (ii) charged to the broker initiating the transaction and/or (iii) charged to operations, based on the particular facts and circumstances. National maintains cash in bank deposits, which, at times, may exceed federally insured limits. National has not experienced and does not expect to experience losses on such accounts. A short sale involves the sale of a security that is not owned in the expectation of purchasing the same security (or a security exchangeable) at a later date at a lower price. A short sale involves the risk of a theoretically unlimited increase in the market price of the security that would result in a theoretically unlimited loss.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Segment Information	20. Segment Information The Company operates in three reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The accounting policies of the Company’s segments are the same as those described in Note 2. Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold. Pharmaceutical and Dermatology Biotechnology ($ in thousands) Products Product Three Months Ended June 30, 2018 Sales Development National Consolidated Net Revenue $ 6,689 126 $ 57,019 $ 63,834 Direct cost of goods (1,668) – – (1,668) Sales and marketing costs (2,910) – – (2,910) Research and development – (17,489) – (17,489) General and administrative (383) (9,763) – (10,146) National expenses – – (56,218) (56,218) Segment income (loss) from operations 1,728 (27,126) 801 (24,597) Segment assets $ 11,307 $ 159,763 65,796 $ 236,866 Pharmaceutical And Dermatology Biotechnology ($ in thousands) Products Product Three Months Ended June 30, 2017 Sales Development National Consolidated Net Revenue $ 4,054 $ 350 $ 46,293 $ 50,697 Direct cost of goods (878) – – (878) Sales and marketing costs (2,610) – – (2,610) Research and development – (13,483) – (13,483) General and administrative (293) (8,231) – (8,524) National expenses – – (48,395) (48,395) Segment loss from operations 273 (21,364) (2,102) (23,193) Segment assets $ 5,447 $ 167,787 $ 76,612 $ 249,846 Pharmaceutical And Dermatology Biotechnology ($ in thousands) Products Product Six Months Ended June 30, 2018 Sales Development National Consolidated Net Revenue $ 12,198 $ 520 $ 106,541 $ 119,259 Direct cost of goods (3,140) – – (3,140) Sales and marketing costs (5,670) – – (5,670) Research and development – (42,544) – (42,544) General and administrative (783) (20,151) – (20,934) National expenses – – (107,054) (107,054) Segment loss from operations $ 2,605 (62,175) $ (513) $ (60,083) Segment assets $ 11,307 159,763 $ 65,796 $ 236,866 Pharmaceutical And Dermatology Biotechnology ($ in thousands) Products Product Six Months Ended June 30, 2017 Sales Development National Consolidated Net Revenue $ 6,139 $ 1,043 $ 88,197 $ 95,379 Direct cost of goods (1,347) - - (1,347) Sales and marketing costs (4,877) - - (4,877) Research and development – (21,887) - (21,887) General and administrative (612) (15,897) - (16,509) National expenses - - (91,529) (91,529) Segment income (loss) from operations $ (697) $ (36,741) $ (3,332) $ (40,770) Segment assets $ 5,447 $ 167,787 $ 76,612 $ 249,846

Revenues from Contracts and Sig

Revenues from Contracts and Significant Customers	6 Months Ended
	Jun. 30, 2018
Revenues [Abstract]
Revenues from Contracts and Significant Customers	21. Revenues from Contracts and Significant Customers Fortress On January 1, 2018, the Company adopted Topic 606 applying the modified retrospective method to all contracts that were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 were presented under Topic 606, while prior period amounts were not adjusted and reported under the accounting standards in effect for the prior periods. Impact to Journey Medical Product Sales Topic 606 does not generally change the practice under which the Company recognizes product revenue from sales of Targadox®, Luxamend® and Ceracade®. The Company’s performance obligation to deliver products is satisfied at the point in time that the goods are delivered to the customer, which is when the customer obtains title to and has the risks and rewards of ownership of the products. The Company’s contracts include variable consideration in the form of refunds for rights of return, price protection, and consideration payable to the customer. As such, for the three months ended June 30, 2018 and 2017, the Company recorded a return reserve of $ 0.7 0.3 Because the Company’s agreements for sales of product to its distributors can be cancelled early, prior to the termination date, they are deemed to have an expected duration of one year or less, and as such, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance Checkpoint Impact to Checkpoint’s Collaboration and License Agreement Revenues Collaboration Agreement with TGTX related to Dana-Farber License In connection with Checkpoint’s license agreement with Dana-Farber, Checkpoint entered into a collaboration agreement with TGTX, a related party, to develop and commercialize the anti-PD-Ll and anti-GITR antibody research programs in the field of hematological malignancies, while the Company retains the right to develop and commercialize these antibodies in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and Fortress’ Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the collaboration agreement, TGTX paid Checkpoint $ 0.5 21.5 7.0 14.5 60.0 0 9,000 44,000 38,000 Collaboration Agreement with TGTX related to Jubliant License In connection with Checkpoint’s license agreement with Jubilant, Checkpoint entered into a sublicense agreement with TGTX, a related party, to develop and commercialize the compounds licensed in the field of hematological malignancies, while the Company retains the right to develop and commercialize these compounds in the field of solid tumors. Michael Weiss, Chairman of the Board of Directors of Checkpoint and Fortress’ Executive Vice Chairman, Strategic Development, is also the Executive Chairman, President and Chief Executive Officer and a stockholder of TGTX. Under the terms of the Sublicense Agreement, TGTX paid Checkpoint $ 1.0 87.2 25.5 61.7 89.0 50 0.1 0.1 0.4 0.6 Sponsored Research Collaboration with NeuPharma, Inc. and TGTX In connection with Checkpoint’s license agreement with NeuPharma, Inc. (“Neupharma”) Checkpoint entered into a Sponsored Research Agreement with NeuPharma for certain research and development activities. Effective January 11, 2016, TGTX agreed to assume all costs associated with this Sponsored Research Agreement and paid Checkpoint for all amounts previously paid. This assumption of costs by TGTX survives any termination or expiration of the option agreement. For the three months ended June 30, 2018 and 2017, Checkpoint recognized approximately nil and $ 0.2 31,000 0.4 The collaborations described above with TGTX each contain a single material performance obligation under Topic 606, which is the granting of a license that is functional intellectual property. Checkpoint’s performance obligation is satisfied at the point in time when the customer has the ability to use and benefit from the right to use the intellectual property. The milestone payments are based on successful achievement of clinical development, regulatory, and sales milestones. Because these payments are contingent on the occurrence of a future event, they represent variable consideration and are constrained and included in the transaction price only when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The sales based royalty payments are recognized as revenue when the subsequent sales occur. Checkpoint also receives variable consideration for certain research and development and patent maintenance related activities that are dependent upon Checkpoint’s actual expenditures under the collaborations and are constrained and included in the transaction price only when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Revenue is recognized approximately when the amounts become due because it relates to an already satisfied performance obligation. For the six months ended June 30, 2018, Checkpoint did not receive any milestone or royalty payments. Disaggregation of Total Revenues Three months ended Six months ended Targadox® $ 6,363 $ 11,861 Other branded revenue 326 337 Total product revenues $ 6,689 $ 12,198 TGTX 126 520 Total Revenue $ 6,815 $ 12,718 Contract Balances and Performance Obligations The Company recognized collaboration and license agreement revenues of $ 0.1 0.5 Significant Customers For the three months ended June 30, 2018, two of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total gross product revenue in the amount of $ 11.5 2.4 4.2 2.2 For the six months ended June 30, 2018, three of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total gross product revenue in the amount of $ 11.5 6.9 5.1 5.3 3.8 At June 30, 2018, two of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 3.9 1.0 At June 30, 2017, two of the Company’s Dermatology Products customers each accounted for more than 10.0% of its total accounts receivable balance in the amount of $ 2.1 0.7 Net Revenue from Pharmaceutical and Biotechnology Product Development represents collaboration revenue from TGTX in connection with Checkpoint and Mustang, which is classified as related party revenue. National Revenue Recognition with Customers National recognizes revenue from contracts with customers when, or as, National satisfies its performance obligations by transferring the promised goods or services to the customers. A good or service is transferred to a customer when, or as, the customer obtains control of that good or service. A performance obligation may be satisfied over time or at a point in time. Revenue from a performance obligation satisfied over time is recognized by measuring progress in satisfying the performance obligation in a manner that depicts the transfer of the goods or services to the customer. Revenue from a performance obligation satisfied at a point in time is recognized at the point in time that National determines the customer obtains control over the promised good or service. The amount of revenue recognized reflects the consideration National expects to be entitled to in exchange for those promised goods or services (i.e., the “transaction price”). In determining the transaction price, National considers multiple factors, including the effects of variable consideration. Variable consideration is included in the transaction price only to the extent it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainties with respect to the amount are resolved. In determining when to include variable consideration in the transaction price, the Company considers the range of possible outcomes, the predictive value of past experiences, the time period of when uncertainties expect to be resolved and the amount of consideration that is susceptible to factors outside of influence, such as market volatility or the judgment and actions of third parties. The following provides detailed information on the recognition of National’s revenues from contracts with customers: Commissions and Other Fees Investment Banking National’s revenues from advisory services primarily consist of fees generated in connection with mergers and acquisition and advisory transactions. Advisory fees from mergers and acquisitions engagements are recognized at a point in time when the related transaction is completed, as the performance obligation is to successfully execute a specific transaction. Fees received prior to the completion of the transaction are deferred within other liabilities on the Condensed Consolidated Balance Sheets. A significant portion of the fees National receives for advisory services are considered variable as they are contingent upon a future event and are excluded from the transaction price until the uncertainty associated with the variable consideration is subsequently resolved, which is expected to occur upon achievement of the specified milestone. Payment for advisory services is generally due promptly upon completion of a specified milestone or, for retainer fees, periodically over the course of the engagement. National recognizes a receivable between the date of completion of the milestone and payment by the customer. Expenses associated with investment banking advisory engagements are deferred only to the extent they are explicitly reimbursable by the client and the related revenue is recognized at a point in time. All other investment banking advisory related costs are expensed as incurred. All investment banking advisory expenses are recognized within their respective expense category on the Condensed Consolidated Statements of Operations and any expenses reimbursed by the clients are recognized as Investment banking revenues. Asset Management Fees. Disaggregation of Revenue ($ in thousands) For the Three For the Six Revenues from customer contracts: Commissions $ 31,407 $ 57,025 Investment banking: Underwriting 6,893 9,593 Private placement 3,484 13,299 Advisory 833 2,147 Other (4) 156 Sub-total National revenue from contracts with customers 42,613 82,220 Other National revenue 14,406 24,321 Total National revenue $ 57,019 $ 106,541 Information on Remaining Performance Obligations and Revenue Recognized from Past Performance National does not disclose information about remaining performance obligations pertaining to contracts that have an original expected duration of one year or less. The transaction price allocated to remaining unsatisfied or partially unsatisfied performance obligations with an original expected duration exceeding one year was not material at March 31, 2018. Investment banking advisory fees that are contingent upon completion of a specific milestone are also excluded as the fees are considered variable and not included in the transaction price at March 31, 2018. Contract Balances The timing of National’s revenue recognition may differ from the timing of payment by customers. National records a receivable when revenue is recognized prior to payment and the Company has an unconditional right to payment. Alternatively, when payment precedes the provision of the related services, National records deferred revenue until the performance obligations are satisfied. Contract Costs Incremental contract costs are expensed when incurred when the amortization period of the asset that would have been recognized is one year or less; otherwise, incremental contract costs are recognized as an asset and amortized over time as services are provided to a customer.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Income taxes The Company and its subsidiaries are subject to US federal and state income taxes. Income tax expense is the total of the current year income tax due or refundable and the change in deferred tax assets and liabilities. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Deferred tax assets are reduced by a valuation allowance when, in the opinion of Management, it is more likely than not that some portion, or all, of the deferred tax asset will not be realized. The Company files a consolidated income tax return with subsidiaries for which the Company has an 80% or greater ownership interest. Subsidiaries for which the Company does not have an 80% or more ownership are not included in the Company’s consolidated income tax group and file their own separate income tax return. As a result, certain corporate entities included in these financial statements are not able to combine or offset their taxable income or losses with other entities’ tax attributes. Income tax expense for the six months ended June 30, 2018 and 2017 is based on the estimated annual effective tax rate. The Company has recorded $ 1.4

Summary of Significant Accoun29

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The unaudited condensed consolidated financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed consolidated financial statements have read or have access to the audited financial statements for the preceding fiscal year for each of the Companies, Avenue, Checkpoint, Mustang and National. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on March 16, 2018, from which the Company derived the balance sheet data at December 31, 2017, as well as National’s Form 10-K and 10-K/A filed with the SEC on December 22, 2017 and January 17, 2018, respectively and their Form 10-Q, filed with the SEC on February 14, 2018, Checkpoint’s Form 10-K filed with the SEC on March 16, 2018, Mustang’s Form 10-K, filed with the SEC on March 29, 2018, and Avenue’s Form 10-K, filed with the SEC on March 1, 2018. The Company’s unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries: Avenue, Aevitas, Caelum, CB Securities, Cellvation, Coronado SO, Checkpoint, Cyprium, Escala, GeneXion, Helocyte, Immune Limited, JMC, Mustang, NHLD, Tamid, Coronado SO, Escala, Fortress China, FBIO Acquisition Corp. IV, FBIO Acquisition Corps. VI – XIV, and JG Pharma, Inc., a subsidiary of JMC. All intercompany balances and transactions have been eliminated. The National assets acquired, and liabilities assumed, and revenues and expenses are reported on a one quarter lag. Therefore, the National assets acquired, and liabilities assumed included in these condensed consolidated financial statements as of June 30, 2018 are actually the assets and liabilities as of March 31, 2018 and the revenues and expenses included in these condensed consolidated financial statements for the quarter ending June 30, 2018 are actually the revenues and expenses for the quarter ending March 31, 2018. The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period.
Use of Estimates	Use of Estimates The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, revenue with customers, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no material changes to the Company’s significant accounting policies previously disclosed in the Company’s Form 10-K filed with the SEC on March 16, 2018, with the exception of revenue recognition.
Recently Issued Accounting Standards	Recently Adopted Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (ASU 2014-09) as modified by ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, ASU 2016-08, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations (Reporting Revenue Gross versus Net), ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing, and ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients.” 0.1 The new revenue guidance does not apply to revenue associated with financial instruments, including National’s warrants and securities that are accounted for under other U.S. GAAP, and as a result, did not have an impact on the elements of the Company’s Condensed Consolidated Statements of Operations most closely associated with financial instruments. The new revenue standard primarily impacts the following of the revenue recognition and presentation accounting policies: ⋅ Investment Banking Revenues ⋅ Investment Banking Advisory Expenses ⋅ Investment Banking Underwriting and Advisory Expenses The new revenue standard requires enhanced disclosures, which are included in Note 21 to the Company’s condensed consolidated financial statements for the three months ended June 30, 2018. Contract Assets Contract assets represent the Company’s right to consideration in exchange for goods or services that the Company has transferred to a customer, excluding unconditional rights to consideration that are presented as receivables. Contract Liabilities Contract liabilities represent the Company’s obligation to deliver products or provide data to customers in the future for which cash has already been received. In May 2017, the FASB issued ASU 2017-09, Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows - Classification of Certain Cash Receipts and Cash Payments In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10) Recent Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326) In July 2017, the FASB issued ASU 2017-11, Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting

National Holdings Corporation30

National Holdings Corporation Acquisition - Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2018
Business Combinations [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class	Intangible assets consist of trademark and customer lists acquired in the offer under the purchase method of accounting and are recorded at fair value net of accumulated amortization since the purchase date. Software license is recorded at cost. Amortization is calculated using the straight-line and accelerated methods over the following estimated useful lives: Useful life Trademark 10 years Customer lists 6 years Software license 3 years
Schedule of Finite-Lived Intangible Assets	Intangible assets at December 31, 2017 $ 14,340 Addition 45 Amortization expense (1,388) Intangible assets at June 30, 2018 $ 12,997
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Trademark Customer Software Total Six Months Ended December 31, 2018 $ 151 $ 1,261 $ 10 $ 1,422 Year Ended December 31, 2019 300 2,500 15 2,815 Year Ended December 31, 2020 301 2,506 15 2,822 Year Ended December 31, 2021 300 2,500 5 2,805 Year Ended December 31, 2022 300 1,726 - 2,026 Thereafter 1,107 — - 1,107 Total $ 2,459 $ 10,493 $ 45 $ 12,997

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	Fortress’s property and equipment, exclusive of National’s property and equipment, consisted of the following ($ in thousands): Estimated Useful June 30, December 31, Computer equipment 3 $ 648 $ 543 Furniture and fixtures 5 1,128 1,009 Machinery and equipment 5 1,897 143 Leasehold improvements 5 – 15 9,181 5,351 Construction in process (1) N/A 864 1,241 Total property and equipment 13,718 8,287 Less: accumulated depreciation (1,674) (1,171) Property and equipment, net $ 12,044 $ 7,116 (1) Relates to the Mustang cell processing facility.
National Holdings Corporation [Member]
Property, Plant and Equipment [Line Items]
Components of Property and Equipment	National’s property and equipment as of March 31, 2018 and September 30, 2017 consisted of the following ($ in thousands): Estimated Useful March 31, September 30, Equipment 5 $ 1,344 $ 1,306 Furniture and fixtures 5 291 284 Leasehold improvements Lesser of useful life or term 1,011 1,006 Capital Leases (primarily composed of computer equipment) 5 276 276 Fixed assets – gross 2,922 2,872 Accumulated depreciation and amortization (803) (475) Fixed asset - net $ 2,119 $ 2,397

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2018
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	Fair Value Measurement as of June 30, 2018 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ - $ - $ 565 $ 565 Total $ - $ - $ 565 $ 565 Liabilities Warrant liabilities $ - $ - $ - $ - Helocyte Convertible Note, at fair value - - 333 333 Caelum Convertible Note, at fair value - - 10,240 10,240 Total $ - $ - $ 10,573 $ 10,573 Fair Value Measurement as of December 31, 2017 ($ in thousands) Level 1 Level 2 Level 3 Total Assets Long-term investments, at fair value $ – $ – $ 1,390 $ 1,390 Total $ – $ – $ 1,390 $ 1,390 Liabilities Warrant liabilities $ – $ – $ 87 $ 87 Caelum Convertible Note, at fair value – – 10,059 10,059 Helocyte Convertible Note, at fair value – – 4,700 4,700 Total $ – $ – $ 14,846 $ 14,846
Schedule of changes in fair value of financial instruments	The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments for the six months ended June 30, 2018: ($ in thousands) Investment in Helocyte Caelum Warrants Warrant Total Balance at December 31, 2017 $ 1,390 $ 4,700 $ 10,059 $ 5,597 $ 87 $ 21,833 Payment of convertible note - (4,076) - - - (4,076) Reclassification of warrant liability from debt to equity - - - (13,615) - (13,615) Change in fair value of investments (825) - - - - (825) Change in fair value of convertible notes - (291) 181 - - (110) Change in fair value of derivative liabilities - - - 8,018 (87) 7,931 Balance at June 30, 2018 $ 565 $ 333 $ 10,240 $ 0 $ 0 $ 11,138
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	Accordingly, at March 15, 2018, the date of the amendment, the fair value of the warrants issued by National (represents 44 13.6 March 15, 2018 Dividend yield – % Expected volatility 59.23 % Risk-free interest rate 2.42 % Life (in years) 3.49 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) National’s Beginning balance at September 30, 2017 $ 5,597 Change in fair value of derivative liability 8,018 Ending balance at March 15, 2018 13,615 Reclassification of warrant to equity (13,615) Ending balance at March 31, 2018 $ –
Helocyte [Member]
Fair Value for Derivative Contingently Issuable Warrant Liabilities	The fair value of Helocyte’s warrant liability, which was issued in connection with Helocyte’s convertible note (see Note 11), as of June 30, 2018 approximated $ 0 0 ($ in thousands) Fair Value of Beginning balance at January 1, 2018 $ 87 Change in fair value of derivative liabilities (87) Ending balance at June 30, 2018 $ –
Helocyte [Member] | Convertible Debt [Member]
Fair Value for Derivative Contingently Issuable Warrant Liabilities	A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Helocyte’s convertible debt that is categorized within Level 3 of the fair value hierarchy as of June 30, 2018, the fair value approximated cost, as the convertible note approaches maturity, is as follows: ($ in thousands) Helocyte Beginning balance at January 1, 2018 $ 4,700 Payment of convertible notes (4,076) Change in fair value of convertible notes (291) Ending balance at June 30, 2018 $ 333
National Warrant Liabilities [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	A summary of the weighted averages (in aggregate) of significant unobservable inputs (Level 3 inputs) used in measuring National’s warrants that are categorized within Level 3 of the fair value hierarchy as of March 31, 2018 is as follows: March 31, 2018 Risk-free interest rate 1.63% – 2.56% Expected dividend yield –% Expected term in years 0.18 – 4.11 Remaining volatility 56.4% – 386.1% Strike price $0.01 – $10.00
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Fair Value of Beginning balance at September 30, 2017 $ 202 Trading revenue gain 1,349 Ending balance at March 31, 2018 $ 1,551
Caelum [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques	Caelum’s convertible debt, which is guaranteed by the Company, is measured at fair value using the Monte Carlo simulation valuation methodology. A summary of the weighted average (in aggregate) significant unobservable inputs (Level 3 inputs) used in measuring Caelum’s convertible debt that is categorized within Level 3 of the fair value hierarchy as of June 30, 2018 is as follows: June 30, 2018 Risk-free interest rate 1.89%- 2.37 % Expected dividend yield - % Expected term in years 0.21 – 1.21 Expected volatility 53.0 %
Fair Value for Derivative Contingently Issuable Warrant Liabilities	($ in thousands) Caelum Beginning balance at January 1, 2018 $ 10,059 Change in fair value of convertible notes 181 Ending balance at June 30, 2018 $ 10,240
National Holdings Corporation [Member]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table shows the fair values hierarchy of National's financial instruments measured at fair value on a recurring basis on the Condensed Consolidated Balance Sheets as of March 31, 2018 and September 30, 2017: Fair Value Measurement as of March 31, 2018 Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 32 $ – $ – $ 32 Municipal bonds – 1,183 – 1,183 Restricted stock – 1,046 – 1,046 Warrants – - 1,551 1,551 Total $ 32 $ 2,229 $ 1,551 $ 3,812 Liabilities National Securities sold, but not yet purchased at fair value: Corporate stocks 2 – – 2 Corporate debt – 6 – 6 Contingent consideration – – 889 889 Total $ 2 $ 6 $ 889 $ 897 Fair Value Measurement as of September 30, 2017 Level 1 Level 2 Level 3 Total Assets National Securities owned, at fair value Corporate stocks $ 116 $ – $ – $ 116 Municipal bonds – 1,239 – 1,239 Restricted stock – 82 – 82 Warrants – – 548 548 Total $ 116 $ 1,321 $ 548 $ 1,985 Liabilities National Securities sold, but not yet purchased at fair value Municipal bonds – 151 – 151 Contingent consideration – – 311 311 Warrants issued - National – – 5,597 5,597 Total $ – $ 151 $ 5,908 $ 6,059

Licenses Acquired (Tables)

Licenses Acquired (Tables)	6 Months Ended
	Jun. 30, 2018
Research and Development Arrangement, Contract to Perform for Others	For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 Fortress $ – $ 300 $ – $ 300 Fortress Companies: Checkpoint – – – 400 Helocyte – – 21 – Mustang – 1,500 75 2,075 Cellvation – – 1 – Caelum – – – 219 Cyprium – – – 100 Aevitas 1 – 1 – Total $ 1 $ 1,800 $ 98 $ 3,094
Schedule of Licenses Acquired Expenses [Table Text Block]	For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 Jubliant Biosys License CK-103 $ – $ – $ – $ 400 Total Licenses Acquired Expense $ – $ – $ – $ 400 For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 City of Hope (COH) IL-13 License $ – $ – $ – $ 250 COH IV/ICV License – – – 125 COH HER2 License – 600 – 600 COH CS-1 License – 600 – 600 COH License for PSCA – 300 – 500 Manufacturing License – – 75 – Total licenses acquired expense $ – $ 1,500 $ 75 $ 2,075

Sponsored Research and Clinic34

Sponsored Research and Clinical Trial Agreements (Tables)	6 Months Ended
	Jun. 30, 2018
Research and Development [Abstract]
Schedule of Expense Related to Clinical Research Arrangements	The table below provides a summary of Helocyte’s expense related to its clinical research arrangements, for the three and six months ended June 30, 2018 and 2017, by agreement as recorded in the Condensed Consolidated Statements of Operations: For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 COH Triplex clinical research and support $ – $ 535 $ – $ 1,035 COH PepVax clinical research and support – – – 235 COH Pentamer clinical research and support 204 12 204 12 Total licenses acquired expense $ 204 $ 547 $ 204 $ 1,282
Schedule of Expense Related to Sponsered Research Arrangements	The table below provides a summary of Mustang’s expense related to its sponsored research agreements, for the three and six months ended June 30, 2018 and 2017, by license as recorded in the Condensed Consolidated Statements of Operations: For the Three Months Ended June 30, For the Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 COH CAR T $ 500 $ 500 $ 1,000 $ 1,000 COH - CD123 114 575 264 595 COH - IL13Ra2 143 1,001 503 1,010 City of Hope – Manufacturing 115 – 229 – Fred Hutch - CD20 418 – 684 – Total $ 1,290 $ 2,076 $ 2,680 $ 2,605

Debt and Interest (Tables)

Debt and Interest (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule Of Interest Expenses	Total debt consists of the following as of June 30, 2018 and December 31, 2017: ($ in thousands) June 30, December 31, Interest Rate Maturity IDB Note $ 14,929 $ 14,929 2.25 % August - 2020 2017 Subordinated Note Financing 3,254 3,254 8.00 % March - 2020 2017 Subordinated Note Financing 13,893 13,893 8.00 % May - 2020 2017 Subordinated Note Financing 1,820 1,820 8.00 % June - 2020 2017 Subordinated Note Financing 3,017 3,018 8.00 % August - 2020 2017 Subordinated Note Financing 6,371 6,371 8.00 % September - 2020 2018 Venture Notes 6,517 – 8.00 % February - 2021 2018 Venture Notes 15,190 – 8.00 % March - 2021 Opus Credit Facility 9,500 9,500 12.00 % September - 2019 Helocyte Convertible Note, at fair value – 1,000 8.00 % December - 2017 Helocyte Convertible Note, at fair value 300 2,194 8.00 % September - 2018 Helocyte Convertible Note, at fair value – 1,062 8.00 % April - 2018 Helocyte Convertible Note, at fair value 23 444 8.00 % November - 2018 Helocyte Convertible Note, at fair value – – 8.00 % September - 2018 Helocyte Convertible Note, at fair value 10 – 8.00 % October - 2018 Caelum Convertible Note, at fair value 1,036 1,017 8.00 % January - 2019 Caelum Convertible Note, at fair value 7,024 6,900 8.00 % February - 2019 Caelum Convertible Note, at fair value 2,180 2,142 8.00 % March - 2019 Total notes payable 85,064 67,544 Less: Discount on notes payable 1,035 1,035 Total notes payable $ 84,029 $ 66,509
Schedule Of Interest Expenses For Debt Arrangements	The following table shows the details of interest expense for all debt arrangements during the periods presented. Interest expense includes contractual interest and amortization of the debt discount and amortization of fees represents fees associated with loan transaction costs, amortized over the life of the loan: Three Months Ended June 30, Six Months Ended June 30, ($ in thousands) 2018 2017 2018 2017 IDB Note Interest $ 85 $ 87 $ 169 $ 169 Total IDB Note 85 87 169 169 NSC Debt Interest – 84 – 155 Amortization of fees – 40 – 73 Total NSC Debt – 124 – 228 2017 Subordinated Note Financing Interest 1,049 406 2,097 406 Amortization of fees 30 175 51 175 Total 2017 Subordinated Note Financing 1,079 581 2,148 581 Opus Credit Facility Interest 284 276 565 508 Amortization of fees 101 241 420 454 Total Opus Note 385 517 985 962 2018 Venture Notes Interest 429 – 485 – Amortization of fees 9 – 10 – Total 2018 Venture Notes 438 – 495 – LOC Fees Interest 9 7 16 15 Total LOC 9 7 16 15 Helocyte Convertible Note Interest 19 57 87 111 Financing fee – – – 1 Total Helocyte Convertible Note 19 57 87 112 Avenue Convertible Note Interest – 5 – 5 Financing fee – - – 3 Total Avenue Convertible Note – 5 – 8 Caelum Convertible Note Interest 195 – 391 – Total Caelum Convertible Note 195 – 391 – Falk CSR Interest (66) – (64) – Total Falk CSR (66) – (64) – D&O Insurance Interest – 2 – 3 Total D&O Insurance – 2 – 3 Total Interest Expense and Financing Fee $ 2,144 $ 1,380 $ 4,227 $ 2,078

Accrued Expenses and Other Lo36

Accrued Expenses and Other Long-Term Liabilities (Tables)	6 Months Ended
	Jun. 30, 2018
Components of Accrued Expenses and Other Long-Term Liabilities	Accrued expenses and other long-term liabilities, excluding National, consisted of the following: June 30, December 31, Accrued Expenses: Professional fees $ 1,535 $ 1,625 Salaries, bonuses and related benefits 3,569 5,279 Accrued expenses - related party 73 95 Research and development 5,143 4,046 Dr. Falk Pharma milestone (See Note 16) 3,365 3,059 Accrued royalties payable 1,268 1,411 Deferred coupon funding 1,777 1,087 Other 779 1,030 Total accrued expenses $ 17,509 $ 17,632 Other long-term liabilities: Deferred rent and long-term lease abandonment charge 4,987 4,739 Total other long-term liabilities $ 4,987 $ 4,739
National Holdings Corporation [Member]
Components of Accrued Expenses and Other Long-Term Liabilities	National’s accounts payable and other accrued expenses as of March 31, 2018 and September 31, 2017, consisted of the following: March 31, 2018 September 30, 2017 Legal $ 615 $ 877 Audit 299 176 Telecommunications 194 205 Data Services 526 464 Regulatory 638 540 Settlements 1,703 2,403 Deferred rent 686 497 Other 2,903 3,242 Total $ 7,564 $ 8,404

Non-Controlling Interests (Tabl

Non-Controlling Interests (Tables)	6 Months Ended
	Jun. 30, 2018
Noncontrolling Interest [Abstract]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net	Non-controlling interests in consolidated entities, as recorded on the Condensed Consolidated Balance Sheets are as follows: As of June 30, 2018 NCI Equity Share Net gain/(loss) attributable Non-controlling interests Non- Aevitas $ (407) $ (184) $ (591) 37.0 % Avenue 2 12,865 (9,631) 3,234 64.5 % Caelum (2,121) (1,474) (3,595) 33.9 % Cellvation (418) (91) (509) 21.6 % Checkpoint 1 24,543 (9,482) 15,061 67.5 % Coronado SO (290) - (290) 13.0 % Cyprium (183) (50) (233) 10.8 % Helocyte (3,203) (91) (3,294) 19.8 % JMC (459) 165 (294) 6.3 % Mustang 2 37,669 (6,729) 30,940 60.0 % National Holdings 15,805 (3,628) 12,177 43.4 % Tamid (164) (110) (274) 24.0 % Total $ 83,637 $ (31,305) $ 52,332 As of December 31, 2017 NCI Equity Share Net gain/(loss) attributable Non-controlling interests Non- Aevitas $ (126) $ (168) $ (294) 35.4 % Avenue 2 17,454 (4,646) 12,808 66.1 % Caelum (815) (1,262) (2,077) 34.7 % Cellvation (259) (96) (355) 21.5 % Checkpoint 1 21,635 (12,314) 9,321 62.0 % Coronado SO (236) (54) (290) 13.0 % Cyprium (143) (15) (158) 11.1 % Helocyte (1,907) (1,193) (3,100) 20.0 % JMC (469) 7 (462) 6.3 % Mustang 2 48,740 (11,911) 36,829 61.6 % National Holdings 17,021 (1,216) 15,805 43.4 % Tamid (6) (92) (98) 24.0 % Total $ 100,889 $ (32,960) $ 67,929 (1) Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights. (2) Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2018
Earnings Per Share [Abstract]
Computations of Diluted Weighted Average Shares Outstanding	The following shares of potentially dilutive securities have been excluded from the computations of diluted weighted average shares outstanding, as the effect of including such securities would be anti-dilutive at the end of the six months ended June 30, 2018 and 2017: Six Months Ended June 30, 2018 2017 Warrants to purchase Common Stock 894,189 603,316 Opus warrants to purchase Common Stock 1,880,000 1,880,000 Options to purchase Common Stock 1,085,502 1,101,193 Convertible Preferred Stock 1,000,000 - Unvested Restricted Stock 11,023,682 9,864,417 Unvested Restricted Stock Units 1,864,980 1,258,372 Total 17,748,353 14,707,298

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Jun. 30, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable	The following table summarizes Fortress stock option activities excluding activity related to Fortress Companies: Number of Weighted Total weighted Weighted average Options vested and expected to vest at December 31, 2017 1,110,501 $ 3.78 $ 1,351,080 3.95 Exercised – – – – Options vested and expected to vest at June 30, 2018 1,110,501 $ 3.78 $ 719,324 3.46 Options vested and exercisable 1,085,501 $ 3.75 $ 719,324 3.43
Nonvested Restricted Stock Shares Activity	The following table summarizes Fortress restricted stock awards and restricted stock units activities, excluding activities related to Fortress Companies: Number of Shares Weighted average Unvested balance at December 31, 2017 11,874,034 $ 2.63 Restricted stock granted 1,392,856 3.99 Restricted stock vested (213,333) 2.76 Restricted stock units granted 405,000 4.18 Restricted stock units forfeited (95,000) 3.49 Restricted stock units vested (130,584) 3.45 Unvested balance at June 30, 2018 13,232,973 $ 2.80
Schedule of Warrant Activities	The following table summarizes Fortress warrant activities, excluding activities related to Fortress Companies: Number of Weighted Total weighted Weighted average Outstanding as of December 31, 2017 2,774,189 $ 3.30 $ 2,204,530 4.47 Granted – – – – Forfeited – – – – Outstanding as of June 30, 2018 2,774,189 $ 3.30 $ 96,600 3.97 Exercisable as of June 30, 2018 869,189 $ 3.96 $ 96,600 3.56

Related Party Transactions (Tab

Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Schedule of Effective Date and Equity Fee Payable	The Company has entered into Founders Agreements and, in some cases, Exchange Agreements with certain of its subsidiaries as described in the Company’s Form 10-K for the year ended December 31, 2017, filed with the SEC on March 16, 2018. The following table summarizes, by subsidiary, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the subsidiaries’ certificates of incorporation. Fortress Company Effective Date (1) PIK Dividend as a % of Class of Stock Issued Helocyte March 20, 2015 2.5 % Common Stock Avenue February 17, 2015 2.5 % Common Stock Mustang March 13, 2015 2.5 % Common Stock Checkpoint March 17, 2015 0.0 % (2) Common Stock Cellvation October 31, 2016 2.5 % Common Stock Caelum January 1, 2017 2.5 % Common Stock Cyprium March 13, 2017 2.5 % Common Stock Aevitas July 28, 2017 2.5 % Common Stock Tamid November 30, 2017 (3) 2.5 % Common Stock (1) Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement. (2) Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5 (3) Represents the Trigger Date.
Schedule of The Effective Date and Annual Management Services agreement Fee Income Expense	The following table summarizes, by subsidiary, the effective date of the MSA and the annual consulting fee payable by the subsidiary to the Company in quarterly installments: Fortress Company Effective Date Annual MSA Fee (Income)/Expense Helocyte March 20, 2015 $ 500 Avenue (1) February 17, 2015 500 Mustang March 13, 2015 500 Checkpoint March 17, 2015 500 Cellvation October 31, 2016 500 Caelum January 1, 2017 500 Cyprium March 13, 2017 500 Aevitas July 28, 2017 500 Tamid November 30, 2017 500 Fortress (4,500) Consolidated (Income)/Expense $ –

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2018
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold. Pharmaceutical and Dermatology Biotechnology ($ in thousands) Products Product Three Months Ended June 30, 2018 Sales Development National Consolidated Net Revenue $ 6,689 126 $ 57,019 $ 63,834 Direct cost of goods (1,668) – – (1,668) Sales and marketing costs (2,910) – – (2,910) Research and development – (17,489) – (17,489) General and administrative (383) (9,763) – (10,146) National expenses – – (56,218) (56,218) Segment income (loss) from operations 1,728 (27,126) 801 (24,597) Segment assets $ 11,307 $ 159,763 65,796 $ 236,866 Pharmaceutical And Dermatology Biotechnology ($ in thousands) Products Product Three Months Ended June 30, 2017 Sales Development National Consolidated Net Revenue $ 4,054 $ 350 $ 46,293 $ 50,697 Direct cost of goods (878) – – (878) Sales and marketing costs (2,610) – – (2,610) Research and development – (13,483) – (13,483) General and administrative (293) (8,231) – (8,524) National expenses – – (48,395) (48,395) Segment loss from operations 273 (21,364) (2,102) (23,193) Segment assets $ 5,447 $ 167,787 $ 76,612 $ 249,846 Pharmaceutical And Dermatology Biotechnology ($ in thousands) Products Product Six Months Ended June 30, 2018 Sales Development National Consolidated Net Revenue $ 12,198 $ 520 $ 106,541 $ 119,259 Direct cost of goods (3,140) – – (3,140) Sales and marketing costs (5,670) – – (5,670) Research and development – (42,544) – (42,544) General and administrative (783) (20,151) – (20,934) National expenses – – (107,054) (107,054) Segment loss from operations $ 2,605 (62,175) $ (513) $ (60,083) Segment assets $ 11,307 159,763 $ 65,796 $ 236,866 Pharmaceutical And Dermatology Biotechnology ($ in thousands) Products Product Six Months Ended June 30, 2017 Sales Development National Consolidated Net Revenue $ 6,139 $ 1,043 $ 88,197 $ 95,379 Direct cost of goods (1,347) - - (1,347) Sales and marketing costs (4,877) - - (4,877) Research and development – (21,887) - (21,887) General and administrative (612) (15,897) - (16,509) National expenses - - (91,529) (91,529) Segment income (loss) from operations $ (697) $ (36,741) $ (3,332) $ (40,770) Segment assets $ 5,447 $ 167,787 $ 76,612 $ 249,846

Revenues from Contracts and S42

Revenues from Contracts and Significant Customers (Tables)	6 Months Ended
	Jun. 30, 2018
Disaggregation of Revenue	Three months ended Six months ended Targadox® $ 6,363 $ 11,861 Other branded revenue 326 337 Total product revenues $ 6,689 $ 12,198 TGTX 126 520 Total Revenue $ 6,815 $ 12,718
Revenue From Contracts With Customers [Member]
Disaggregation of Revenue	The following presents National’s revenues from contracts with customers disaggregated by major business activity for the three months ended June 30, 2018: ($ in thousands) For the Three For the Six Revenues from customer contracts: Commissions $ 31,407 $ 57,025 Investment banking: Underwriting 6,893 9,593 Private placement 3,484 13,299 Advisory 833 2,147 Other (4) 156 Sub-total National revenue from contracts with customers 42,613 82,220 Other National revenue 14,406 24,321 Total National revenue $ 57,019 $ 106,541

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Additional Information (Detail) $ in Millions	Jan. 02, 2018USD ($)
Accounting Policies [Line Items]
National investment banking expenses	$ 0.1

National Holdings Corporation44

National Holdings Corporation Acquisition - Intangible Assets - Amortization is calculated using the straight-line method over the estimated useful lives (Detail)	6 Months Ended
	Jun. 30, 2018
Trademark [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	10 years
Customer Lists [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	6 years
Software license [Member]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	3 years

National Holdings Corporation45

National Holdings Corporation Acquisition - Intangible Assets - gross carrying amounts related to acquired intangible assets (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Intangible assets at December 31, 2017	$ 14,340
Addition	45
Amortization expense	(1,388)	$ (819)
Intangible assets at June 30, 2018	$ 12,997

National Holdings Corporation46

National Holdings Corporation Acquisition - Intangible Assets - future amortization of these intangible assets (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Total	$ 13,614	$ 15,223
National Holdings Corporation [Member]
Six Months Ended December 31, 2018	1,422
Year Ended December 31, 2019	2,815
Year Ended December 31, 2020	2,822
Year Ended December 31, 2021	2,805
Year Ended December 31, 2022	2,026
Thereafter	1,107
Total	12,997
Customer Lists [Member]
Six Months Ended December 31, 2018	1,261
Year Ended December 31, 2019	2,500
Year Ended December 31, 2020	2,506
Year Ended December 31, 2021	2,500
Year Ended December 31, 2022	1,726
Thereafter	0
Total	10,493
Software license [Member]
Six Months Ended December 31, 2018	10
Year Ended December 31, 2019	15
Year Ended December 31, 2020	15
Year Ended December 31, 2021	5
Year Ended December 31, 2022	0
Thereafter	0
Total	45
Trademarks [Member]
Six Months Ended December 31, 2018	151
Year Ended December 31, 2019	300
Year Ended December 31, 2020	301
Year Ended December 31, 2021	300
Year Ended December 31, 2022	300
Thereafter	1,107
Total	$ 2,459

Broker-Dealers and Clearing O47

Broker-Dealers and Clearing Organizations, Other Receivables and Prepaid Expenses and Other Current Liabilities - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations	$ 11,412		$ 7,395
Broker -Dealers And clearing Organisation [Member]
Brokers And Dealers [Line Items]
Receivables from Brokers-Dealers and Clearing Organizations		$ 11,400		$ 7,400
Allowance for Doubtful Accounts Receivable		500		500
Broker -Dealers And clearing Organisation [Member] | Other Receivable [Member]
Brokers And Dealers [Line Items]
Accounts Receivable, Net		$ 6,000		$ 5,200

Forgivable Loans Receivable - A

Forgivable Loans Receivable - Additional Information (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017
Notes, Loans and Financing Receivable, Net, Current	$ 1,598	$ 300	$ 1,616	$ 400
Forgivable Loan Receivable [Member]
Debt Instrument, Interest Rate, Stated Percentage	4.00%

Property and Equipment - Additi

Property and Equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
Depreciation			$ 831	$ 543
National Holdings Corporation [Member]
Property, Plant and Equipment [Line Items]
Depreciation	$ 200	$ 100	300	200
Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Depreciation	$ 300	$ 200	$ 500	$ 400

Property and Equipment - Compon

Property and Equipment - Components of Property and Equipment (Detail) - USD ($) $ in Thousands		6 Months Ended
		Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Total property and equipment			$ 2,922		$ 2,872
Less: accumulated depreciation			(803)		(475)
Property and equipment, net		$ 14,163	2,119	$ 9,513	2,397
Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		13,718		8,287
Less: accumulated depreciation		(1,674)		(1,171)
Property and equipment, net		12,044		7,116
Computer equipment [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 648		543
Useful Life (Years)		3 years
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment			291		284
Useful Life (Years)		5 years
Furniture and fixtures [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 1,128		1,009
Useful Life (Years)		5 years
Machinery and equipment [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 1,897		143
Useful Life (Years)		5 years
Leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment			$ 1,011		$ 1,006
Leasehold improvements [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 9,181		5,351
Leasehold improvements [Member] | Fortress Biotech Inc [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)		15 years
Leasehold improvements [Member] | Fortress Biotech Inc [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Useful Life (Years)		5 years
Construction in process [Member] | Fortress Biotech Inc [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	[1]	$ 864		$ 1,241
[1]	Relates to the Mustang cell processing facility

Property and Equipment - Schedu

Property and Equipment - Schedule Of Interest Expenses For Debt Arrangements (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 2,922		$ 2,872
Less: accumulated depreciation		(803)		(475)
Property and equipment, net	$ 14,163	2,119	$ 9,513	2,397
Equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		1,344		1,306
Property Plant And Equipment Useful Life	5 years
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		291		284
Property Plant And Equipment Useful Life	5 years
Leaseholds And Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		1,011		1,006
Property, Plant and Equipment, Estimated Useful Lives	Lesser of useful life or term
Capital leases (primarily composed of computer equipment) [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment		$ 276		$ 276
Property Plant And Equipment Useful Life	5 years

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	5 Months Ended	6 Months Ended
	Mar. 15, 2018	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total		$ 800,000
Investment Owned, at Fair Value		3,812,000	$ 1,985,000
Helocyte [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value, Beginning Balance		0	$ 87,000
Debt Conversion, Converted Instrument, Amount		0
Origo Acquisition Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investment Owned, at Fair Value		$ 600,000
Fair Value Assumptions Probability Of Business Combination		13.93%
Working Capital Note Convertible To Equity		$ 300,000
National Holdings Corporation [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants	44.00%
Warrants Not Settleable in Cash, Fair Value Disclosure	$ 13,600,000
Binomial Lattice Model [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Exercise Price		$ 0.18
Binomial Lattice Model [Member] | Warrant [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Acquisition, Share Price		0.30
Private Units [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Share Price		$ 1.80

Fair Value Measurements - Warra

Fair Value Measurements - Warrant Liabilities And Convertible Notes At Fair Value (Detail) - $ / shares	5 Months Ended	6 Months Ended
	Mar. 15, 2018	Jun. 30, 2018	Mar. 31, 2018
Warrants Issuable [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate	2.42%
Expected dividend yield	0.00%
Expected term in years	3 years 5 months 26 days
Expected volatility	59.23%
National Warrant Liabilities [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield			0.00%
National Warrant Liabilities [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		1.89%	1.63%
Expected term in years			2 months 5 days
Strike price			$ 0.01
Remaining volatility			56.40%
National Warrant Liabilities [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Risk-free interest rate		2.37%	2.56%
Expected term in years			4 years 1 month 10 days
Strike price			$ 10
Remaining volatility			386.10%
Caelum Convertible Notes [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected dividend yield		0.00%
Expected volatility		53.00%
Caelum Convertible Notes [Member] | Minimum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term in years		2 months 16 days
Caelum Convertible Notes [Member] | Maximum [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Expected term in years		1 year 2 months 16 days

Fair Value Measurements - Deriv

Fair Value Measurements - Derivative Contingently Issuable Warrant liabilities (Detail) - USD ($) $ in Thousands	1 Months Ended	5 Months Ended	6 Months Ended
	Mar. 31, 2018	Mar. 15, 2018	Jun. 30, 2018	Mar. 31, 2018
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Payment of convertible notes			$ (4,076)
Reclassification of warrant to equity			(13,615)
National [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:	$ 13,615	$ 5,597		$ 5,597
Trading revenue gain		8,018
Reclassification of warrant to equity	(13,615)
Fair value at end of period:	0	13,615		0
Helocyte [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:			87
Change in fair value			(87)
Fair value at end of period:			0
Helocyte [Member] | Convertible Debt [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:			4,700
Payment of convertible notes			(4,076)
Change in fair value			(291)
Fair value at end of period:			333
National Warrant Liabilities [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:		$ 202		202
Change in fair value				1,349
Fair value at end of period:	$ 1,551			$ 1,551
Caelum Convertible Notes [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Fair value at the beginning of period:			10,059
Change in fair value			181
Fair value at end of period:			$ 10,240

Fair Value Measurements - Natio

Fair Value Measurements - National Financial Instruments Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Assets
Long-term investments, at fair value	$ 565		$ 1,390
Total	565		1,390
Liabilities
Liabilities	10,573		14,846
Convertible Debt [Member]
Liabilities
Liabilities		$ 6
National Holdings Corporation [Member]
Assets
Total		3,812		$ 1,985
Liabilities
Liabilities		897		6,059
Warrant [Member]
Liabilities
Liabilities	0		87
Warrant [Member] | National Holdings Corporation [Member]
Assets
Total		1,551		548
Helocyte Convertible Note One [Member]
Liabilities
Liabilities	333		4,700
Corporate stock Assets [Member]
Liabilities
Liabilities		2
Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		32		116
Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		1,183		1,239
Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		1,046		82
Municipal bonds Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				151
Contingent Consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		889		311
Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				5,597
Caelum Convertible Notes [Member]
Liabilities
Liabilities	10,240		10,059
Fair Value, Inputs, Level 1 [Member]
Assets
Long-term investments, at fair value	0		0
Total	0		0
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | Convertible Debt [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 1 [Member] | National Holdings Corporation [Member]
Assets
Total		32		116
Liabilities
Liabilities		2		0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | Warrant [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 1 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 1 [Member] | Corporate stock Assets [Member]
Liabilities
Liabilities		2
Fair Value, Inputs, Level 1 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		32		116
Fair Value, Inputs, Level 1 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 1 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 1 [Member] | Municipal bonds Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				0
Fair Value, Inputs, Level 1 [Member] | Contingent Consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0		0
Fair Value, Inputs, Level 1 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				0
Fair Value, Inputs, Level 1 [Member] | Caelum Convertible Notes [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member]
Assets
Long-term investments, at fair value	0		0
Total	0		0
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | Convertible Debt [Member]
Liabilities
Liabilities		6
Fair Value, Inputs, Level 2 [Member] | National Holdings Corporation [Member]
Assets
Total		2,229		1,321
Liabilities
Liabilities		6		151
Fair Value, Inputs, Level 2 [Member] | Warrant [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | Warrant [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 2 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 2 [Member] | Corporate stock Assets [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 2 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 2 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		1,183		1,239
Fair Value, Inputs, Level 2 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		1,046		82
Fair Value, Inputs, Level 2 [Member] | Municipal bonds Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				151
Fair Value, Inputs, Level 2 [Member] | Contingent Consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		0		0
Fair Value, Inputs, Level 2 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				0
Fair Value, Inputs, Level 2 [Member] | Caelum Convertible Notes [Member]
Liabilities
Liabilities	0		0
Fair Value, Inputs, Level 3 [Member]
Assets
Long-term investments, at fair value	565		1,390
Total	565		1,390
Liabilities
Liabilities	10,573		14,846
Fair Value, Inputs, Level 3 [Member] | Convertible Debt [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member] | National Holdings Corporation [Member]
Assets
Total		1,551		548
Liabilities
Liabilities		889		5,908
Fair Value, Inputs, Level 3 [Member] | Warrant [Member]
Liabilities
Liabilities	0		87
Fair Value, Inputs, Level 3 [Member] | Warrant [Member] | National Holdings Corporation [Member]
Assets
Total		1,551		548
Fair Value, Inputs, Level 3 [Member] | Helocyte Convertible Note One [Member]
Liabilities
Liabilities	333		4,700
Fair Value, Inputs, Level 3 [Member] | Corporate stock Assets [Member]
Liabilities
Liabilities		0
Fair Value, Inputs, Level 3 [Member] | Corporate stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 3 [Member] | Municipal bonds Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 3 [Member] | Restricted stock Assets [Member] | National Holdings Corporation [Member]
Assets
Total		0		0
Fair Value, Inputs, Level 3 [Member] | Municipal bonds Liabilities [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				0
Fair Value, Inputs, Level 3 [Member] | Contingent Consideration [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities		$ 889		311
Fair Value, Inputs, Level 3 [Member] | Warrants Issuable [Member] | National Holdings Corporation [Member]
Liabilities
Liabilities				$ 5,597
Fair Value, Inputs, Level 3 [Member] | Caelum Convertible Notes [Member]
Liabilities
Liabilities	$ 10,240		$ 10,059

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Fair Value of Financial Instruments (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	$ 21,833
Payment of convertible notes	(4,076)
Reclassification of warrant liability from debt to equity	(13,615)
Change in fair value of investments	(825)
Change in fair value of convertible notes	(110)
Change in fair value of derivative liabilities	7,931
Balance	11,138
Helocyte Convertible Note At Fair Value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	4,700
Payment of convertible notes	(4,076)
Reclassification of warrant liability from debt to equity	0
Change in fair value of investments	0
Change in fair value of convertible notes	(291)
Change in fair value of derivative liabilities	0
Balance	333
Warrants Issued Issuable [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	5,597
Payment of convertible notes	0
Reclassification of warrant liability from debt to equity	(13,615)
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	8,018
Balance	0
Caelum Convertible Notes, at fair value [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	10,059
Payment of convertible notes	0
Reclassification of warrant liability from debt to equity	0
Change in fair value of investments	0
Change in fair value of convertible notes	181
Change in fair value of derivative liabilities	0
Balance	10,240
Warrant liabilities [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	87
Payment of convertible notes	0
Change in fair value of investments	0
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	(87)
Balance	0
Investment In Origo [Member]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance	1,390
Payment of convertible notes	0
Reclassification of warrant liability from debt to equity	0
Change in fair value of investments	(825)
Change in fair value of convertible notes	0
Change in fair value of derivative liabilities	0
Balance	$ 565

Licenses Acquired - Additional

Licenses Acquired - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process	$ 1	$ 1,800	$ 98	$ 3,094
Caelum [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process	0	0	0	200
Cyprium [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research And Development In Process	$ 0	$ 0	$ 0	$ 100

Licenses Acquired - Summary Of

Licenses Acquired - Summary Of Research and Development Arrangement Contract (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 1	$ 1,800	$ 98	$ 3,094
Fortress [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	300	0	300
Checkpoint Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	0	0	400
Helocyte [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	0	21	0
Mustang Therapeutics, Inc [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	1,500	75	2,075
Cellvation [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	0	1	0
Caelum Biosciences, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	0	0	219
Cyprium Therapeutics, Inc. [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	0	0	0	$ 100
Aevitas [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Research and Development Total	$ 1	$ 0	$ 1

Licenses Acquired - license as

Licenses Acquired - license as recorded in the Condensed Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Research And Development In Process	$ 1	$ 1,800	$ 98	$ 3,094
Checkpoint Therapeutics, Inc [Member]
Research And Development In Process	0	0	0	400
Checkpoint Therapeutics, Inc [Member] | Jubliant Biosys License CK-103 [Member]
Research And Development In Process	0	0	0	400
Mustang Therapeutics, Inc [Member]
Research And Development In Process	0	1,500	75	2,075
Mustang Therapeutics, Inc [Member] | City of Hope (COH) IL-13 License [Member]
Research And Development In Process	0	0	0	250
Mustang Therapeutics, Inc [Member] | COH IV/ICV License [Member]
Research And Development In Process	0	0	0	125
Mustang Therapeutics, Inc [Member] | COH HER2 License [Member]
Research And Development In Process	0	600	0	600
Mustang Therapeutics, Inc [Member] | COH CS-1 License [Member]
Research And Development In Process	0	600	0	600
Mustang Therapeutics, Inc [Member] | COH License for PSCA [Member]
Research And Development In Process	0	300	0	500
Mustang Therapeutics, Inc [Member] | Manufacturing License [Member]
Research And Development In Process	$ 0	$ 0	$ 75	$ 0

Sponsored Research and Clinic60

Sponsored Research and Clinical Trial Agreements - Additional Information (Detail) - USD ($)	Mar. 12, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Columbia University [Member]
Research And Development Expense		$ 27,000		$ 38,000
Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross	$ 100,000
University of Texas [Member]
Research And Development Expense		100,000	$ 100,000	200,000	$ 200,000
University of North Carolina [Member]
Research And Development Expense		200,000		400,000
Checkpoint Therapeutics, Inc [Member]
Research And Development Expense		0	$ 200,000	31,000	$ 400,000
Umass Sponsored Research Agreement [Member]
Research And Development Expense		30,000		400,000
Sponsor Research Agreement, Funding Commitment		800,000		800,000
Payments For Research And Development Expenses				800,000
UNC Sponsored Research Agreement [Member]
Sponsor Research Agreement, Funding Commitment		$ 2,300,000		2,300,000
UNC Sponsored Research Agreement [Member] | Tamid [Member]
Payments For Research And Development Expenses				$ 800,000

Sponsored Research and Clinic61

Sponsored Research and Clinical Trial Agreements - summary of Helocyte’s expense related to its clinical research arrangements (Detail) - Helocyte Inc [Member] - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Payments For Research And Development Expenses	$ 204	$ 547	$ 204	$ 1,282
COH Triplex Clinical Research and Support [Member]
Payments For Research And Development Expenses	0	535	0	1,035
COH PepVax Clinical Research And Support [Member]
Payments For Research And Development Expenses	0	0	0	235
COH Pentamer clinical research and support [Member]
Payments For Research And Development Expenses	$ 204	$ 12	$ 204	$ 12

Sponsored Research and Clinic62

Sponsored Research and Clinical Trial Agreements - summary of Mustang’s expense related to its sponsored research agreements (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Research And Development In Process	$ 1	$ 1,800	$ 98	$ 3,094
Mustang Therapeutics Inc [Member]
Research And Development In Process	1,290	2,076	2,680	2,605
COH CAR T [Member] | Mustang Therapeutics Inc [Member]
Research And Development In Process	500	500	1,000	1,000
COH - CD123 [Member] | Mustang Therapeutics Inc [Member]
Research And Development In Process	114	575	264	595
COH - IL13Ra2 [Member] | Mustang Therapeutics Inc [Member]
Research And Development In Process	143	1,001	503	1,010
City of Hope - Manufacturing [Member] | Mustang Therapeutics Inc [Member]
Research And Development In Process	115	0	229	0
Fred Hutch - CD20 [Member] | Mustang Therapeutics Inc [Member]
Research And Development In Process	$ 418	$ 0	$ 684	$ 0

Intangibles, net - Additional I

Intangibles, net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets			$ 45	$ 0
Cost of Goods Sold, Amortization			266	267
Journey Medical Corporation [Member]
Indefinite-lived Intangible Assets [Line Items]
Payments to Acquire Intangible Assets			1,600
Cost of Goods Sold, Amortization	$ 100	$ 100	$ 300	$ 300

Debt and Interest- Additional I

Debt and Interest- Additional Information (Detail) - USD ($) $ in Thousands	Mar. 12, 2018	Mar. 31, 2018	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Debt [Line Items]
Payments of Financing Costs			$ 0	$ 1,939
Opus Credit Facility [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			12.00%
Debt instrument Expiration Period	Sep. 14, 2019				Sep. 14, 2018
Venture Notes [Member]
Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		8.00%
Debt Instrument, Face Amount		$ 21,700
Debt Instrument, Term			36 months
Debt Instrument, Maturity Date, Description			The notes mature 36 months from issuance, provided that during the first 24 months the Company may extend the maturity date by six months.
NSC [Member] | Venture Notes [Member]
Debt [Line Items]
Warrant On Sale Price Of Note Percentage			25.00%
Payments of Financing Costs		$ 1,700
Class of Warrant or Right, Expiration Period			10 years
Aevitas Therapeutics, Inc [Member] | Venture Notes [Member]
Debt [Line Items]
Proceeds from Notes Payable			$ 1,400
Tamid Bio, Inc [Member] | Venture Notes [Member]
Debt [Line Items]
Proceeds from Notes Payable			1,100
Cellvation [Member] | Venture Notes [Member]
Debt [Line Items]
Proceeds from Notes Payable			1,200
Cyprium [Member] | Venture Notes [Member]
Debt [Line Items]
Proceeds from Notes Payable			$ 1,000

Debt and Interest - Long-term d

Debt and Interest - Long-term debt (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Debt [Line Items]
Total notes payable	$ 85,064	$ 67,544
Less: Discount of notes payable	1,035	1,035
Total notes payable, net	84,029	66,509
IDB Note [Member]
Debt [Line Items]
Total notes payable	$ 14,929	14,929
Interest Rate	2.25%
Maturity Date	August - 2020
2017 Subordinated Note Financing One [Member]
Debt [Line Items]
Total notes payable	$ 3,254	3,254
Interest Rate	8.00%
Maturity Date	March - 2020
2017 Subordinated Note Financing Two [Member]
Debt [Line Items]
Total notes payable	$ 13,893	13,893
Interest Rate	8.00%
Maturity Date	May - 2020
2017 Subordinated Note Financing Three [Member]
Debt [Line Items]
Total notes payable	$ 1,820	1,820
Interest Rate	8.00%
Maturity Date	June - 2020
2017 Subordinated Note Financing Four [Member]
Debt [Line Items]
Total notes payable	$ 3,017	3,018
Interest Rate	8.00%
Maturity Date	August - 2020
2017 Subordinated Note Financing Five [Member]
Debt [Line Items]
Total notes payable	$ 6,371	6,371
Interest Rate	8.00%
Maturity Date	September - 2020
2018 Venture Notes One [Member]
Debt [Line Items]
Total notes payable	$ 6,517	0
Interest Rate	8.00%
Maturity Date	February - 2021
2018 Venture Notes Two [Member]
Debt [Line Items]
Total notes payable	$ 15,190	0
Interest Rate	8.00%
Maturity Date	March - 2021
Opus Credit Facility [Member]
Debt [Line Items]
Total notes payable	$ 9,500	9,500
Interest Rate	12.00%
Maturity Date	September - 2019
Helocyte Convertible Note One [Member]
Debt [Line Items]
Total notes payable	$ 0	1,000
Maturity Date	December - 2017
Helocyte Convertible Note One [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Two [Member]
Debt [Line Items]
Total notes payable	$ 300	2,194
Maturity Date	September - 2018
Helocyte Convertible Note Two [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Three [Member]
Debt [Line Items]
Total notes payable	$ 0	1,062
Maturity Date	April - 2018
Helocyte Convertible Note Three [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note four [Member]
Debt [Line Items]
Total notes payable	$ 23	444
Maturity Date	November - 2018
Helocyte Convertible Note four [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Five [Member]
Debt [Line Items]
Total notes payable	$ 0	0
Maturity Date	September - 2018
Helocyte Convertible Note Five [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Helocyte Convertible Note Six [Member]
Debt [Line Items]
Total notes payable	$ 10	0
Maturity Date	October - 2018
Helocyte Convertible Note Six [Member] | Maximum [Member]
Debt [Line Items]
Interest Rate	8.00%
Caelum Convertible Note one [Member]
Debt [Line Items]
Total notes payable	$ 1,036	1,017
Interest Rate	8.00%
Maturity Date	January - 2019
Caelum Convertible Note Two [Member]
Debt [Line Items]
Total notes payable	$ 7,024	6,900
Interest Rate	8.00%
Maturity Date	February - 2019
Caelum Convertible Note one Three [Member]
Debt [Line Items]
Total notes payable	$ 2,180	$ 2,142
Interest Rate	8.00%
Maturity Date	March - 2019

Debt and Interest - Schedule of

Debt and Interest - Schedule of Interest Expenses for Debt Arrangements (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Debt [Line Items]
Total Interest Expense and Financing Fee	$ 2,144	$ 1,380	$ 4,227	$ 2,078
LOC Fees [Member]
Debt [Line Items]
Interest	9	7	16	15
Interest and Debt Expense	9	7	16	15
IDB Note [Member]
Debt [Line Items]
Interest	85	87	169	169
Interest and Debt Expense	85	87	169	169
NSC Debt [Member]
Debt [Line Items]
Interest	0	84	0	155
Amortization of fees	0	40	0	73
Interest and Debt Expense	0	124	0	228
2017 Subordinated Note Financing [Member]
Debt [Line Items]
Interest	1,049	406	2,097	406
Amortization of fees	30	175	51	175
Interest and Debt Expense	1,079	581	2,148	581
Opus Credit Facility [Member]
Debt [Line Items]
Interest	284	276	565	508
Amortization of fees	101	241	420	454
Interest and Debt Expense	385	517	985	962
2018 Venture Notes [Member]
Debt [Line Items]
Interest	429	0	485	0
Amortization of fees	9	0	10	0
Interest and Debt Expense	438	0	495	0
Helocyte Convertible Note [Member]
Debt [Line Items]
Interest	19	57	87	111
Financing fee	0	0	0	1
Interest and Debt Expense	19	57	87	112
Avenue Convertible Note [Member]
Debt [Line Items]
Interest	0	5	0	5
Financing fee	0	0	0	3
Interest and Debt Expense	0	5	0	8
Caelum Convertible Notes [Member]
Debt [Line Items]
Interest	195	0	391	0
Interest and Debt Expense	195	0	391	0
Falk CSR [Member]
Debt [Line Items]
Interest	(66)	0	(64)	0
Interest and Debt Expense	(66)	0	(64)	0
D&O Insurance [Member]
Debt [Line Items]
Interest	0	2	0	3
Interest and Debt Expense	$ 0	$ 2	$ 0	$ 3

Accrued Expenses and Other Lo67

Accrued Expenses and Other Long-Term Liabilities - Components of Accrued Expenses and Other Long-Term Liabilities (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Accrued Expenses:
Professional fees	$ 1,535	$ 1,625
Salaries, bonuses and related benefits	3,569	5,279
Accrued expenses - related party	73	95
Research and development	5,143	4,046
Dr. Falk Pharma milestone	3,365	3,059
Accrued royalties payable	1,268	1,411
Deferred coupon funding	1,777	1,087
Other	779	1,030
Total accrued expenses	17,509	17,632
Other long-term liabilities:
Deferred rent and long-term lease abandonment charge	4,987	4,739
Total other long-term liabilities	$ 4,987	$ 4,739

Accrued Expenses and Other Lo68

Accrued Expenses and Other Long-Term Liabilities- Accounts Payable and Other Accrued Expenses (Detail) - USD ($) $ in Thousands	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Sep. 30, 2017
Legal	$ 1,535		$ 1,625
Other	779		1,030
Total	$ 38,126		$ 36,127
National Holdings Corporation [Member]
Legal		$ 615		$ 877
Audit		299		176
Telecommunications		194		205
Data Services		526		464
Regulatory		638		540
Settlements		1,703		2,403
Deferred rent		686		497
Other		2,903		3,242
Total		$ 7,564		$ 8,404

Non-Controlling Interests - Sum

Non-Controlling Interests - Summary Of Non-controlling Interests in Consolidated Entities (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended		12 Months Ended
		Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Noncontrolling Interest [Line Items]
NCI equity share				$ 83,637		$ 100,889
Net gain/(loss) attributable to non-controlling interests		$ (14,105)	$ (5,584)	(31,305)	$ (8,164)	(32,960)
Non-controlling interests in consolidated entities		52,332		52,332		67,929
Avenue [Member]
Noncontrolling Interest [Line Items]
NCI equity share	[1]			12,865		17,454
Net gain/(loss) attributable to non-controlling interests	[1]			(9,631)		(4,646)
Non-controlling interests in consolidated entities	[1]	$ 3,234		$ 3,234		$ 12,808
Non-controlling ownership	[1]	64.50%		64.50%		66.10%
Coronado SO [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ (290)		$ (236)
Net gain/(loss) attributable to non-controlling interests				0		(54)
Non-controlling interests in consolidated entities		$ (290)		$ (290)		$ (290)
Non-controlling ownership		13.00%		13.00%		13.00%
Mustang Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	[1]			$ 37,669		$ 48,740
Net gain/(loss) attributable to non-controlling interests	[1]			(6,729)		(11,911)
Non-controlling interests in consolidated entities	[1]	$ 30,940		$ 30,940		$ 36,829
Non-controlling ownership	[1]	60.00%		60.00%		61.60%
Checkpoint Therapeutics, Inc [Member]
Noncontrolling Interest [Line Items]
NCI equity share	[2]			$ 24,543		$ 21,635
Net gain/(loss) attributable to non-controlling interests	[2]			(9,482)		(12,314)
Non-controlling interests in consolidated entities	[2]	$ 15,061		$ 15,061		$ 9,321
Non-controlling ownership	[2]	67.50%		67.50%		62.00%
JMC [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ (459)		$ (469)
Net gain/(loss) attributable to non-controlling interests				165		7
Non-controlling interests in consolidated entities		$ (294)		$ (294)		$ (462)
Non-controlling ownership		6.30%		6.30%		6.30%
Helocyte [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ (3,203)		$ (1,907)
Net gain/(loss) attributable to non-controlling interests				(91)		(1,193)
Non-controlling interests in consolidated entities		$ (3,294)		$ (3,294)		$ (3,100)
Non-controlling ownership		19.80%		19.80%		20.00%
Cellvation [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ (418)		$ (259)
Net gain/(loss) attributable to non-controlling interests				(91)		(96)
Non-controlling interests in consolidated entities		$ (509)		$ (509)		$ (355)
Non-controlling ownership		21.60%		21.60%		21.50%
Caelum [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ (2,121)		$ (815)
Net gain/(loss) attributable to non-controlling interests				(1,474)		(1,262)
Non-controlling interests in consolidated entities		$ (3,595)		$ (3,595)		$ (2,077)
Non-controlling ownership		33.90%		33.90%		34.70%
National Holdings [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ 15,805		$ 17,021
Net gain/(loss) attributable to non-controlling interests				(3,628)		(1,216)
Non-controlling interests in consolidated entities		$ 12,177		$ 12,177		$ 15,805
Non-controlling ownership		43.40%		43.40%		43.40%
Aevitas [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ (407)		$ (126)
Net gain/(loss) attributable to non-controlling interests				(184)		(168)
Non-controlling interests in consolidated entities		$ (591)		$ (591)		$ (294)
Non-controlling ownership		37.00%		37.00%		35.40%
Cyprium [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ (183)		$ (143)
Net gain/(loss) attributable to non-controlling interests				(50)		(15)
Non-controlling interests in consolidated entities		$ (233)		$ (233)		$ (158)
Non-controlling ownership		10.80%		10.80%		11.10%
Tamid [Member]
Noncontrolling Interest [Line Items]
NCI equity share				$ (164)		$ (6)
Net gain/(loss) attributable to non-controlling interests				(110)		(92)
Non-controlling interests in consolidated entities		$ (274)		$ (274)		$ (98)
Non-controlling ownership		24.00%		24.00%		24.00%
[1]	Avenue and Mustang are consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Preferred Class A Shares which provide super-majority voting rights.
[2]	Checkpoint is consolidated with Fortress’ operations because Fortress maintains voting control through its ownership of Checkpoint’s Class A Common Shares which provide super-majority voting rights.

Net Loss per Common Share - Com

Net Loss per Common Share - Computations of Diluted Weighted Average Shares Outstanding (Detail) - shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	17,748,353	14,707,298
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,000,000	0
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	894,189	603,316
Opus warrants to purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,880,000	1,880,000
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,085,502	1,101,193
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	11,023,682	9,864,417
Unvested Restricted Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total of weighted average shares outstanding	1,864,980	1,258,372

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Mar. 12, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Stock Purchase Plan to eligible employees, compensation expense recognized		$ 43,000	$ 40,000	$ 81,000	$ 75,000
Share-based Compensation				8,623,000	7,736,000
Adjustments To Additional Paid In Capital At Market Offering Costs				$ (141,000)
Market Offering [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Issued, Price Per Share		$ 3.60		$ 3.60
Proceeds from issuance of Common stock				$ 4,100,000
Issuance of Common Stock for At the Market Offering in shares				1,130,835
Adjustments To Additional Paid In Capital At Market Offering Costs				$ 71,000
Checkpoint [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares Issued, Price Per Share	$ 4.35
Proceeds from issuance of Common stock	$ 20,800,000
Stock Issued During Period, Shares, New Issues	5,290,000
Stock Issued During Period, Value, New Issues	$ 23,000,000
Payments of Stock Issuance Costs	2,200,000
Available-for-sale Securities	$ 77,000,000
Research and Development Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 800,000	2,400,000	3,100,000	3,200,000
General and Administrative Expense [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 2,800,000	$ 2,400,000	$ 5,500,000	$ 4,300,000
Restricted Stock [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				2 years 10 months 24 days
Share-based Compensation				$ 12,400,000
Restricted Stock Units (RSUs) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition					2 years 3 months 18 days
Share-based Compensation					$ 2,700,000
Employee Stock Option [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Employee Stock Purchase Plan to eligible employees, Reckoning fair value percentage during offering period		85.00%		85.00%
Common Stock issued in connection with the first ESPP offering				289,359
Common Stock, Capital Shares Reserved for Future Issuance		110,641		110,641

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Programs (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 3,570	$ 4,807	$ 8,623	$ 7,736
National [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	418	183	676	184
Avenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	322	19	671	24
Checkpoint [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	72	2,382	1,209	3,362
Mustang [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	972	397	2,966	397
Other [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	198	113	30	213
Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	1,121	1,150	2,063	2,424
Executive Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	444	540	962	1,096
Non-Employee Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 23	$ 23	$ 46	$ 36

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Option Activity (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Options Outstanding	1,110,501
Number of shares, Options Exercised	0
Number of shares, Options Outstanding	1,110,501	1,110,501
Number of shares, Options Exercisable	1,085,501
Weighted Average Exercise Price, Options Exercised	$ 0
Total Weighted Average Intrinsic Value, Options Exercised	$ 0
Total Weighted Average Intrinsic Value, Options vested and exercisable	$ 719,324
Weighted Average Remaining Contractual Life, Options Exercisable	3 years 5 months 16 days	3 years 11 months 12 days
Weighted average exercise price, Options vested and expected to vest	$ 3.78
Weighted average exercise price, Options vested and expected to vest	3.78	$ 3.78
Weighted average exercise price, Options vested and exercisable	$ 3.75
Total Weighted average intrinsic value, Options vested and expected to vest	$ 1,351,080
Total Weighted average intrinsic value, Options vested and expected to vest	$ 719,324	$ 1,351,080
Weighted average remaining contractual life (years), Options vested and expected to vest	3 years 5 months 16 days	3 years 11 months 12 days
Weighted average remaining contractual life (years), Options vested and exercisable	3 years 5 months 5 days

Stockholders' Equity - Restrict

Stockholders' Equity - Restricted Stock Activity (Detail) - Restricted Stock [Member]	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares, Unvested balance | shares	11,874,034
Number of shares, Restricted stock granted | shares	1,392,856
Number of shares, Restricted stock vested | shares	(213,333)
Number of shares, Restricted stock units granted | shares	405,000
Number of shares, Restricted stock units forfeited | shares	(95,000)
Number of shares, Restricted stock units vested | shares	(130,584)
Number of shares, Unvested balance | shares	13,232,973
Weighted average grant price, Unvested balance | $ / shares	$ 2.63
Weighted average grant price, Restricted stock granted | $ / shares	3.99
Weighted average grant price, Restricted stock vested | $ / shares	2.76
Weighted average grant price, Restricted stock units granted | $ / shares	4.18
Weighted average grant price, Restricted stock units forfeited | $ / shares	3.49
Weighted average grant price, Restricted stock units vested | $ / shares	3.45
Weighted average grant price, Unvested balance | $ / shares	$ 2.8

Stockholders' Equity - Summariz

Stockholders' Equity - Summarizes Fortress warrant activities (Detail) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Subsidiary or Equity Method Investee [Line Items]
Weighted average remaining contractual life, Forfeited (years)	0 years
Warrant [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of shares, Outstanding	2,774,189
Number of shares, Granted	0
Forfeited	0
Number of shares, Outstanding	2,774,189	2,774,189
Number of shares, Exercisable	869,189
Weighted average exercise price, Outstanding	$ 3.3
Weighted average exercise price, Granted	0
Weighted average exercise price, Forfeited	0
Weighted average exercise price, Outstanding	3.3	$ 3.3
Weighted average exercise price, Exercisable	$ 3.96
Total weighted average intrinsic value, Outstanding	$ 2,204,530
Total weighted average intrinsic value, Granted	0
Total weighted average intrinsic value, Forfeited	0
Total weighted average intrinsic value, Outstanding	96,600	$ 2,204,530
Total weighted average intrinsic value, Exercisable	$ 96,600
Weighted average remaining contractual life, Granted (years)	0 years
Weighted average remaining contractual life (years), Outstanding	3 years 11 months 19 days	4 years 5 months 19 days
Weighted average remaining contractual life, Exercisable (years)	3 years 6 months 22 days

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) € in Millions	Jul. 12, 2018USD ($)	Jul. 27, 2017EUR (€)	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Jun. 30, 2018	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Sep. 30, 2017USD ($)
Operating Leased Assets [Line Items]
Loss Contingency, Accrual, Current			$ 1,700,000			$ 1,700,000		$ 2,400,000
Loss Contingency Accrual, Provision			400,000	$ 1,000,000		700,000	$ 1,000,000
Legal Fees			$ 0	$ 300,000		$ 300,000	$ 800,000
Business Combination, Contingent Consideration Arrangements, Description					Fortress contended that no such payment is due because a condition of the EUR 2.5 million payment was the delivery of a Clinical Study Report that addressed the primary and secondary objectives of a Phase II trial, and Fortress contended that Dr. Falk Pharma failed to deliver such a Clinical Study Report. Dr. Falk Pharma filed a lawsuit against Fortress in the above-referenced Court in Frankfurt, Germany to recover the EUR 2.5 million plus interest and attorneys fees, and Fortress filed an answer to the complaint, denying that it had any liability to Dr. Falk Pharma.
Subsequent Event [Member]
Operating Leased Assets [Line Items]
Loss Contingency, Damages Sought, Value	$ 3,300,000
Administration Fee Payable	$ 37,000
Dr. Falk Pharma [Member]
Operating Leased Assets [Line Items]
Proceeds from Legal Settlements | €		€ 2.5

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Feb. 02, 2018
Related Party Transaction [Line Items]
Lease Sharing Agreements Contributions To Property Under Lease			$ 96,000
Description Of Fee Paid			NSC received a fee of approximately $1.8 million, or 8% on the gross proceeds raised of $23.0 million. The fees were eliminated in consolidation.
Proceeds from Other Debt			$ 21,707,000	$ 0
Noninterest Expense Transfer Agent and Custodian Fees			$ 1,700,000
National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Business Acquisition, Percentage of Voting Interests Acquired	56.30%		56.30%
Opus Credit Facility [Member]
Related Party Transaction [Line Items]
Payments of Loan Costs			$ 300,000	500,000
Debt Instrument, Interest Rate, Stated Percentage	12.00%		12.00%
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Interest own in percent by principal stockholder or director	13.70%		13.70%
Board of Directors Chairman [Member] | National Holdings Corporation [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	4.60%		4.60%
TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Due from Related Parties, Current	$ 43,000		$ 43,000
Checkpoint [Member] | Chord Advisors, LLC [Member]
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party		$ 0
Founders Agreement [Member] | Avenue Therapeutics, Inc. [Member]
Related Party Transaction [Line Items]
Other Fee,Percentage			2.50%
OPPM [Member]
Related Party Transaction [Line Items]
Payments for Rent			$ 42,000
Due from Related Parties, Current	$ 10,000		$ 10,000
Executives Vice Chairman [Member]
Related Party Transaction [Line Items]
Interest own in percent by principal stockholder or director	16.00%		16.00%
Collaborative Agreements with TGTX [Member]
Related Party Transaction [Line Items]
Proceeds from Option Fee					$ 50,000
Desk Share Agreements [Member]
Related Party Transaction [Line Items]
Payments for Rent			$ 600,000
Desk Share Agreements [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Due from Related Parties, Current	$ 0		0
Desk Share Agreements [Member] | OPPM [Member]
Related Party Transaction [Line Items]
Due from Related Parties, Current	94,000		94,000
Shared Services Agreement [Member] | TG Therapeutics, Inc [Member]
Related Party Transaction [Line Items]
Proceeds from Related Party Agreement	700,000	$ 400,000	1,000,000	$ 600,000
Due from Related Parties	$ 400,000		$ 400,000

Related Party Transactions - Sc

Related Party Transactions - Schedule of Effective Date and Equity Fee Payable (Detail)	6 Months Ended
	Jun. 30, 2018
Helocyte Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 20, 2015	[1]
Avenue Therapeutics, Inc. [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Feb. 17, 2015	[1]
Mustang Bio, Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 13, 2015	[1]
Checkpoint Therapeutics, Inc [Member]
Dividends, Paid-in-kind,Percentage	0.00%	[2]
Dividends Payable, Date Declared	Mar. 17, 2015	[1]
Cellvation Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Oct. 31, 2016	[1]
Caelum Biosciences, Inc. [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Jan. 1, 2017	[1]
Cyprium Biosciences, Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Mar. 13, 2017	[1]
Aevitas Inc [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Jul. 28, 2017	[1]
Tamid [Member]
Dividends, Paid-in-kind,Percentage	2.50%
Dividends Payable, Date Declared	Nov. 30, 2017	[1],[3]
[1]	Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement.
[2]	Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.
[3]	Represents the Trigger Date.

Related Party Transactions - 79

Related Party Transactions - Schedule of The Effective Date and Annual Management Services agreement Fee (Income) Expense (Detail) $ in Thousands	6 Months Ended
	Jun. 30, 2018USD ($)
Annual Management Services Agreement Fee Income Expense	$ 0
Helocyte Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 20, 2015
Avenue Therapeutics, Inc. [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Feb. 17, 2015	[1]
Mustang Bio, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 13, 2015
Checkpoint Therapeutics, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 17, 2015
Cellvation Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Oct. 31, 2016
Caelum Biosciences, Inc. [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Jan. 1, 2017
Cyprium Biosciences, Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Mar. 13, 2017
Fortress Biotech Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ (4,500)
Aevitas Inc [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Jul. 28, 2017
Tamid [Member]
Annual Management Services Agreement Fee Income Expense	$ 500
Annual Consulting Fee Payable Effective Date	Nov. 30, 2017
[1]	Represents the effective date of each subsidiary’s Founders Agreement. Each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement.

Net Capital Requirements of B80

Net Capital Requirements of Broker-Dealer Subsidiaries - Additional Information (Detail) - National Securities [Member]	Mar. 31, 2018USD ($)
Net Capital	$ 11,900,000
Excess Net Capital at 1000 Percent	10,900,000
Minimum Net Capital Required for Broker-Dealer Subsidiary	$ 1,000,000

Segment Information - Operating

Segment Information - Operating Results by Reportable Segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net Revenue	$ 63,834	$ 50,697	$ 119,259	$ 95,379
Direct cost of goods	(1,668)	(878)	(3,140)	(1,347)
Sales and marketing costs	(2,910)	(2,610)	(5,670)	(4,877)
Research and development	(17,489)	(13,483)	(42,544)	(21,887)
General and administrative	(10,146)	(8,524)	(20,934)	(16,509)
National expenses	88,431	73,890	179,342	136,149
Segment income (loss) from operations	(24,597)	(23,193)	(60,083)	(40,770)
Segment assets	236,866		236,866		$ 245,950
Dermatology Products Sales [Member]
Segment Reporting Information [Line Items]
Net Revenue	6,689	4,054	12,198	6,139
Direct cost of goods	(1,668)	(878)	(3,140)	(1,347)
Sales and marketing costs	(2,910)	(2,610)	(5,670)	(4,877)
Research and development	0	0	0	0
General and administrative	(383)	(293)	(783)	(612)
National expenses	0	0	0	0
Segment income (loss) from operations	1,728	273	2,605	(697)
Segment assets	11,307	5,447	11,307	5,447
Pharmaceutical And Biotechnology Product Development [Member]
Segment Reporting Information [Line Items]
Net Revenue	126	350	520	1,043
Direct cost of goods	0	0	0	0
Sales and marketing costs	0	0	0	0
Research and development	(17,489)	(13,483)	(42,544)	(21,887)
General and administrative	(9,763)	(8,231)	(20,151)	(15,897)
National expenses	0	0	0	0
Segment income (loss) from operations	(27,126)	(21,364)	(62,175)	(36,741)
Segment assets	159,763	167,787	159,763	167,787
National [Member]
Segment Reporting Information [Line Items]
Net Revenue	57,019	46,293	106,541	88,197
Direct cost of goods	0	0	0	0
Sales and marketing costs	0	0	0	0
Research and development	0	0	0	0
General and administrative	0	0	0	0
National expenses	(56,218)	(48,395)	(107,054)	(91,529)
Segment income (loss) from operations	801	(2,102)	(513)	(3,332)
Segment assets	65,796	76,612	65,796	76,612
Consolidated [Member]
Segment Reporting Information [Line Items]
National expenses		(48,395)		(91,529)
Segment assets	$ 236,866	$ 249,846	$ 236,866	$ 249,846

Revenues from Contracts and S82

Revenues from Contracts and Significant Customers - Additional Information (Detail) - USD ($)	May 11, 2015	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017	Jun. 30, 2018	Mar. 31, 2018	Jun. 30, 2017
Revenue Recognition Milestone Method Payments Due					$ 500,000
License and Services Revenue		$ 100,000			500,000
Return Reserve		$ 700,000		$ 300,000	700,000		$ 300,000
Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]
Revenue Recognition, Milestone Method, Revenue Recognized			$ 100,000	100,000	400,000		600,000
Payment Of Upfront Licensing Fee					$ 1,000,000
Research And Development Cost Shared Percentage		50.00%			50.00%
Checkpoint Collaboration Agreement with TGTX NeuPharma, Inc. and TGTX [Member]
Revenue Recognition, Milestone Method, Revenue Recognized		$ 0		200,000	$ 31,000		400,000
Customer One [Member]
Sales Revenue, Goods, Gross		11,500,000		4,200,000	11,500,000		5,300,000
Accounts Receivable, Net		3,900,000		2,100,000	3,900,000		2,100,000
Customer Two [Member]
Sales Revenue, Goods, Gross		2,400,000		2,200,000	6,900,000		3,800,000
Accounts Receivable, Net		1,000,000		$ 700,000	1,000,000		$ 700,000
Customer Three [Member]
Sales Revenue, Goods, Gross					5,100,000
First Commercial Sale Milestone [Member] | Checkpoint Therapeutics, Inc [Member]
Revenue Recognition Milestone Method Payments Due					21,500,000
Additional Sales Milestone [Member] | Checkpoint Therapeutics, Inc [Member]
Revenue Recognition Milestone Method Payments Due					60,000,000
Clinical Development Milestone [Member] | Checkpoint Therapeutics, Inc [Member]
Revenue Recognition Milestone Method Payments Due		0			7,000,000	$ 0
Commercial Sales In Specified Territories [Member] | Checkpoint Therapeutics, Inc [Member]
Revenue Recognition Milestone Method Payments Due					14,500,000
Successful Achievement Of One Preclinical Milestone [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]
Revenue Recognition Milestone Method Payments Due					25,500,000
Clinical Development And Regulatory Milestones [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]
Revenue Recognition Milestone Method Payments Due					87,200,000
Five Regulatory Approvals And First Commercial Sales [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]
Maximum Potential Milestone Payments		61,700,000			61,700,000
Sale Millstone [Member] | Checkpoint Collaboration Agreement with TGTX related to Jubliant License [Member]
Maximum Potential Milestone Payments		$ 89,000,000			$ 89,000,000
Dana Farber Cancer Institute [Member]
Proceeds from issuance of Common stock	$ 10,000,000

Revenues from Contracts and S83

Revenues from Contracts and Significant Customers - Company’s product revenue (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Sales Revenue, Goods, Net	$ 6,689		$ 12,198
Total Revenue	63,834	$ 50,697	119,259	$ 95,379
TGTX [Member]
Sales Revenue, Goods, Net	126		520
Targadox [Member]
Sales Revenue, Goods, Net	6,363		11,861
Other branded revenue [Member]
Sales Revenue, Goods, Net	$ 326		$ 337

Revenues from Contracts and S84

Revenues from Contracts and Significant Customers - presents National’s revenues (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Commissions	$ 31,407	$ 57,025
Investment banking:
Underwriting	6,893	9,593
Private placement	3,484	13,299
Advisory	833	2,147
Other	(4)	156
Sub-total National revenue from contracts with customers	42,613	82,220
Other National revenue	14,406	24,321
Total National revenue	$ 57,019	$ 106,541

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Tax Disclosure [Line Items]
Income Tax Expense (Benefit)	$ 1,438	$ 0	$ 1,438	$ 0